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ABSTRACT 
DANIEL HERTZ: Pharmacogenetic Predictors of Taxane-Induced Peripheral 
Neuropathy  
 (Under the direction of Dr. Howard L. McLeod) 
Peripheral neuropathy is an adverse event of taxane treatment that is 
related both to the patient’s cumulative drug exposure and their inherent 
sensitivity to neurotoxicity. Discovery and validation of genetic loci that determine 
neuropathy risk is an important first step towards individualization of taxane 
treatment with the ultimate goal of maximizing treatment efficacy and minimizing 
the risk of severe adverse events.  
Paclitaxel exposure is regulated by enzymes and transporters that have 
common variants known to influence protein expression or activity. Paclitaxel is 
primarily metabolized by the CYP2C8 enzyme, and prior research from our group 
and others suggests that patients who carry a common low-activity variant, 
CYP2C8*3, may be at increased risk of neuropathy. Using a cohort of paclitaxel-
treated breast cancer patients, I was able to confirm the association between 
CYP2C8*3 and increased risk of paclitaxel-induced peripheral neuropathy.  
I then attempted to use a genotyping platform that interrogates thousands 
of variants in hundreds of genes relevant to drug metabolism, elimination, and 
transport to identify polymorphisms that influence risk of neurotoxicity after 
accounting for the CYP2C8*3 variant. Surprisingly, I discovered a polymorphism 
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in a gene not thought to be relevant to paclitaxel pharmacokinetics, ABCG1, 
which was associated with neuropathy risk.  
Less is known about the clinical or genetic factors that modulate 
docetaxel-induced neuropathy risk. I performed genome-wide association in a 
large cohort of docetaxel-treated patients to discover genetic loci that modulate 
risk of neuropathy. I discovered several candidates, one of which was an 
intergenic polymorphism that surpassed genome-wide significance after 
adjustment for relevant clinical covariates. 
I then attempted, unsuccessfully, to replicate these discoveries in 
independent cohorts of taxane-treated patients. This inability to replicate 
indicates that either the associations of these variants are limited to the cohort in 
which they were discovered or that they were merely spurious discoveries. 
Replication should be attempted in independent patient cohorts that are more 
similar to those in which these discoveries were made to validate the influence of 
these variants on neuropathy risk, enabling translation into routine clinical 
practice. 
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 CHAPTER I 
INTRODUCTION 
 
TAXANE DISCOVERY AND FORMULATION  
The taxanes are a class of chemotherapeutic agents that are highly 
efficacious for the treatment of a wide array of cancer types. The original taxane, 
paclitaxel (Taxol), was isolated from the Pacific Yew tree Taxus brevifolia in the 
early 1970s after a crude extract of the bark demonstrated cytotoxic activity in a 
screening protocol(1). Due to solubility issues, paclitaxel was developed with a 
formulation vehicle, Cremophor EL, which enabled intravenous administration(2). 
Even before approval there were foreseeable issues with Cremophor, leading to 
investigations into alternative vehicles such as triacetin(3) and a continued effort 
toward developing alternative paclitaxel formulations such as encapsulation in 
liposomes(4) or bound to albumin (Abraxane) which has received Food and Drug 
Administration (FDA) approval(5). 
Production of a kilogram of pure paclitaxel required the destruction of 
thousands of Taxus brevifolia trees, spawning understandable fears about the 
continued supply of drug(6). This provoked efforts toward culturing bark in the 
lab, producing synthetic paclitaxel, or producing paclitaxel from similar 
compounds found in the endlessly renewable needles of the Yew tree(7). These 
investigations led to the development of the semi-synthetic docetaxel (Taxotere) 
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which is based off of a starting material isolated from the needles of the Taxus 
baccata(8) and demonstrated superior in vitro cytotoxicity in pre-clinical structure-
activity studies of paclitaxel analogs(9, 10). Docetaxel had solubility issues of its 
own, which were overcome by formulation with polysorbate (Tween) 80(11). 
Almost a half decade later a fully synthetic pathway for paclitaxel production was 
discovered(12, 13), assuaging fears of a taxane supply shortage. Taxoids with 
superior pharmacological or pharmaceutical properties continue to be developed, 
such as the recently FDA approved cabazitaxel (Jevtana)(14), or the currently in-
development tesetaxel (DJ-927)(15). Due to the lack of clinical experience and 
knowledge of these agents only paclitaxel and docetaxel in their original 
formulations (herein referred to as taxanes) will be considered for the remainder 
of this dissertation.  
ADME AND PHARMACOKINETICS 
Because it was the first in its class, reports of paclitaxel mechanism, 
pharmacokinetics, and optimal clinical utilization generally outnumber those of 
docetaxel. The absorption, distribution, metabolism and excretion (ADME) 
properties of the two taxanes are more similar than different, beginning with the 
intravenous-only administration of both compounds necessitated by the lack of 
solubility(2). After introduction into the systemic circulation, in which the taxanes 
are highly protein bound to both albumin and alpha 1-acid glycoprotein (AAG) 
(16, 17), their strong hydrophobicity leads to extensive drug diffusion throughout 
the body(18). Both drugs, in addition to passive diffusion, are substrates for a 
number of transporters including active uptake by OATP1B3(19, 20) into 
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hepatocytes. Here, however, is a major difference between the ADME of the 
taxanes. Docetaxel, like many other drugs, is metabolized mainly by 
CYP3A4/5(21) while paclitaxel is metabolized primarily by CYP2C8(22) with a 
minor contribution from CYP3A4(23, 24) at a site distinct from that metabolized 
on docetaxel(25). Systemic concentrations of the hydroxylated metabolites of 
both taxanes are negligible as they are eliminated immediately after formation via 
MRP2 transport into the biliary system(26, 27); and the metabolites are not 
thought to contribute to either the efficacy or toxicity of the parent compound(28-
30). Pre-clinical rat studies revealed that very little paclitaxel is eliminated via the 
kidneys(31), which is consistent with estimates of <5% renal elimination in early 
clinical studies of both paclitaxel(32) and docetaxel(33). Another route of taxane 
elimination is direct P-glycoprotein (P-gp) efflux(34, 35), which is important in a 
variety of ways. P-gp is expressed in the intestine, and a large portion of taxane 
elimination occurs through this direct intestinal efflux(36). Perhaps just as 
important for taxane pharmacology is that P-gp is over-expressed in many 
tumors and functions as a cancer resistance mechanism by extruding cytotoxic 
agents from the cell cytoplasm(34, 37). 
The similarity in taxane ADME leads to general pharmacokinetic (PK) 
similarity. Both taxanes follow three-compartment pharmacokinetics, though 
docetaxel PK is linear(38, 39) while paclitaxel demonstrates saturable kinetic 
behavior(40) caused by micellular encapsulation in Cremophor EL(41). More 
recent models that account for Cremophor concentration or measure only free 
paclitaxel demonstrate linear kinetic behavior of the free parent compound(42). 
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Population pharmacokinetic models have improved our ability to detect and 
understand factors that influence pharmacokinetic behavior. For both paclitaxel 
and docetaxel, patient age, BSA, liver function (bilirubin level), and AAG 
influence drug exposure but it is unclear whether the influence of other factors 
such as sex(43) or hormone levels(44) are limited to only one taxane. 
Regardless, after accounting for these variables 15-25% of inter-individual 
variability in estimates of free paclitaxel or docetaxel clearance remain 
unexplained(40, 45).   
MECHANISM AND INDICATIONS 
The taxanes work by binding to microtubules(46); protein pipes that form 
the mitotic spindle during chromosomal separation, among other tasks necessary 
for cellular growth and replication(47, 48). Microtubules, comprised of two 
subunits (α and β), exist in a state of ‘dynamic stability’ in which assembly and 
disassembly remain in balance. The taxanes specifically bind to the same 
binding site(49) on the β-subunit(50, 51) and interfere with microtubule 
disassembly(52). Disruption of dynamic stability leads to accumulation of 
microtubules and inability to form the spindle centromeres(53) which is 
necessary for mitosis. This causes cells to remain in the G2/M replication 
phase(54) inducing cellular apoptosis(55).  
Both paclitaxel and docetaxel have been tested pre-clinically and in early 
clinical studies in a variety of tumor types. Despite the broadly positive results of 
these early clinical studies, Food and Drug Administration (FDA) approval for 
both paclitaxel (breast, ovarian, non-small cell lung cancer, AIDS-related 
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Kaposi’s Sarcoma)(56) and docetaxel (breast, non-small cell lung, hormone 
refractory prostate, gastric adenocarcinoma, squamous cell carcinoma of the 
head and neck)(57) is limited to specific indications in just a few tumor types.  
TOXICITY PROFILE AND DOSE-LIMITING TOXICITY 
Similar to other chemotherapeutic agents, the taxanes are highly toxic and 
are administered at the highest dose that is associated with an acceptable risk of 
severe toxicity (maximum tolerated dose [MTD]). During the original dose-
escalation studies, the primary dose limiting toxicities of paclitaxel were infusion-
related ‘hypersensitivity’(58) and leukopenia(59). In subsequent studies 
pretreatment with granulocyte colony-stimulating factor (Filgrastim) was used to 
overcome the hematologic toxicity(60). The infusion reaction, which may not be 
true hypersensitivity, can also be circumvented through the use of prophylactic 
antihistamines(61) and successful re-challenge with pretreatment and slower 
infusion has been reported without incident(62). Prevention of these original 
dose-limiting toxicities enabled further escalation, to a dose at which peripheral 
neuropathy is the most common, severe toxicity associated with paclitaxel 
treatment(32).  
Similarly, patients taking docetaxel are pretreated to limit certain adverse 
events, such as fluid retention(63) and hypersensitivity(64). MTD studies with 
docetaxel reported concurrent severe granulocytopenia and mucositis(65), and 
identified neutropenia, a specific myelotoxicity characterized by a decrease in 
neutrophils, as docetaxel’s predominant dose limiting toxicity(33). Severe 
neutropenia is sometimes associated with a fever of unknown origin, a 
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dangerous syndrome called febrile neutropenia that often requires 
rehospitalization and can be fatal(66). Though it’s not often treatment limiting, 
docetaxel is also associated with sensory peripheral neurotoxicity, but for 
reasons not entirely clear the incidence of severe, grade 3 or higher (grade 3+) 
peripheral neuropathy tends to be lower with docetaxel (1%-7%) than paclitaxel 
(2.5%-9%) in head-to-head studies(67-70).  
TAXANE-INDUCED PERIPHERAL NEUROPATHY 
Mechanism 
Microtubules are necessary for formation of peripheral neurons, 
specifically the development of neuronal axons(71). It is unsurprising, then, that 
neuropathy is a characteristic toxicity of many microtubule targeting agents, 
including those outside of the taxane class such as the vinca alakaloids and the 
epothilones(72, 73). However, despite a vast research effort within in vitro and 
animal systems, it is not clear what the true mechanism of taxane-induced 
peripheral neuropathy (TIPN) is. Early in pre-clinical development it was 
discovered that in vitro paclitaxel treatment of spinal neurites from dorsal route 
ganglia led to microtubule accumulation(74) and inhibition of neurite branching 
and growth(75). There is also evidence from these in vitro studies that Schwann 
cells may be a primary site of action for taxanes(76) leading to decreased myelin 
production and myelination of neuronal axons(77). These effects on neurons and 
Schwann cells have been confirmed in studies of paclitaxel treated rats in which 
both neuronal axons and Schwann cells accumulated microtubules(78). 
Interestingly, all of these effects resolved over time, normal Schwann cell 
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function and axonal myelination were restored within 6 months of treatment 
discontinuation(79, 80). Our knowledge of the neurotoxic effects in humans is 
very limited but a biopsy of a sural nerve from a paclitaxel treated patient 
confirmed that axonal demyelination and atrophy occur in vivo(81). 
Description  
TIPN manifests in a “glove-and-stocking” presentation with symptoms 
beginning symmetrically in the fingers and toes and spreading inward to the 
hands and feet(73, 82). Most patients originally describe a tingling sensation(83) 
which will progress to numbness and loss of function of the affected extremities 
with continued treatment(84). Discontinuation of therapy typically impedes the 
progression of neuropathy and in most cases the patient’s symptoms will 
dissipate over time(85, 86), recapitulating the findings from the previously 
described animal studies. Descriptively the neuropathy seen with paclitaxel and 
docetaxel are very similar and it is unclear why there is a difference in incidence 
between the agents. The paclitaxel vehicle Cremophor EL is known to be 
somewhat neurotoxic(11), however, paclitaxel formulations that do not include 
Cremophor still induce neuropathy(87), indicating that paclitaxel itself is the 
principal neurotoxin(88). Perhaps differences in distribution, specifically to the 
dorsal route ganglia, or affinity for or uptake within neurons or Schwann cells 
explains the difference between taxanes, though head-to-head comparison in a 
rat model indicated similar neuropathy incidence and severity between the two 
taxanes(89) so perhaps the mechanism is specific to humans.  
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Risk Factors  
Risk factors for taxane-induced neuropathy, particularly for paclitaxel, 
have been reported from analyses in large patient cohorts. The primary risk 
factor is increased drug exposure, with cumulative dose administered being the 
strongest predictor for neuropathy development(85, 90-93). Beyond cumulative 
dose, the exposure to a single dose as measured by either the paclitaxel area 
under the curve (AUC)(94) or the amount of time paclitaxel concentration 
remains above a threshold level(95, 96) influence risk of neuropathy, suggesting 
that cumulative exposure to the free compound is the most important risk factor. 
Some comparative clinical studies of paclitaxel infusion times and frequencies 
have suggested differences in neurotoxicity for 24 hour vs. 1 hour infusions and 
tri-weekly vs. weekly schedules(97, 98). However, the results of these studies 
are not entirely consistent(99), and are difficult to interpret due to non-uniformity 
in the cumulative dose received between the comparator arms. Interestingly, in a 
meta-analysis of the studies comparing the weekly vs. 3-weekly schedule the 
dose intensity (mg/m2/week) was a stronger predictor of neuropathy risk than the 
schedule(100), suggesting that differences in exposure from treatment schedules 
and/or non-linear pharmacokinetics likely explain the differences in neuropathy 
seen among the different treatment schedules, duration times, and doses. By 
extension, the previously discussed factors that influence drug exposure such as 
age, BSA, drug binding, and sex are likely to influence neuropathy risk. The data 
on the association with patient age is somewhat inconclusive(101-103); while 
most of the other factors have not been directly studied.  
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Aside from differences in drug administration or exposure, some patients 
are inherently sensitive to taxane-induced neuropathy. One group of patients 
who are at increased risk are those with prior neuropathy(92, 104) either from 
previous chemotherapy(105) or secondary to comorbidities such as diabetes or 
alcohol abuse(106, 107). There is also evidence that the risk of paclitaxel-
induced neuropathy is higher in African-Americans than Caucasians(108, 109). 
Whether this reflects an inherent sensitivity or there are currently unappreciated 
differences in drug exposure between races is currently unknown.  
GERMLINE GENETIC VARIABILITY AND PHARMACOGENETICS (PGX) 
Based on the available evidence, neuropathy risk is determined in part by 
exposure to the offending agent and in part by inherent patient sensitivity. Both of 
these factors are themselves influenced by a multitude of inputs which form a 
complex network of processes that ultimately results in the unpredictable and 
unexplainable variability in the development of taxane-induced peripheral 
neuropathy. 
One factor that may be responsible for some of the observed variability is 
variation in germline genetics(110). Small changes in the DNA code can lead to 
dramatic changes in gene transcription(111), post-transcriptional 
processing(112), or protein activity(113) among other possible influences on 
biology(114). These seemingly minor changes in DNA sequence can have 
clinically relevant downstream effects on drug pharmacokinetics or 
pharmacodynamics(115).  
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Examples of putative genetic alterations that influence pharmacotherapy 
outcomes are catalogued and evaluated by various organizations(116-118). 
Inclusion of this information into the drug package insert by the FDA is viewed as 
regulatory validation that the genetic marker could be useful in clinical 
practice(119). A number of pharmacogenetic markers have surpassed this 
stringent level of validation, including the use of genetic markers in common drug 
metabolizing enzymes or transporters such as: CYP2C19(120), CYP2D6(121), 
CYP2C9(122), UGT1A1(123) and SLCO1B3(124). Similarly, markers in genes 
relevant to drug mechanism or etiology of adverse events have also been 
validated including: VKORC1(125), IL28B(126), and the HLA system(127-129).  
Pharmacogenetics of Taxane-Induced Peripheral Neuropathy 
Discovery and validation of the genetic loci that determine the risk of TIPN 
are the first steps toward the clinical use of patient genetics in treatment 
individualization. Early work utilized a candidate-gene approach and focused 
primarily on single nucleotide polymorphisms (SNPs) involved in taxane 
metabolism and elimination in small patient cohorts. Because of the lack of rigid 
statistical methodology, many of the findings of these studies are likely to be 
false positives(130), necessitating replication in independent cohorts of patients. 
The first SNP reported to modulate risk of paclitaxel-induced neuropathy is the 
CYP2C8*3 (rs10509681 K399R, rs11572080 R139K) variant(131). This finding 
was replicated once by Leskela et al.(132) and I was able to replicate it in a sub-
analysis of a small patient cohort (Appendix 1)(133). As with most PGx 
associations, other studies have not replicated these results(134-137), 
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necessitating replication in additional cohorts of patients with a priori defined 
analysis plans and rigorous statistical methodology. Leskela et al. also reported 
that the CYP2C8 haplotype-C SNP (rs1113129) and CYP3A5*3C are protective 
for risk of paclitaxel-induced neuropathy, however these findings could not be 
replicated by Gréen et al.(138). Similarly inconsistent findings have been 
reported for three linked SNPs in the ABCB1 gene and their influence on 
paclitaxel(139) and docetaxel(140) induced neuropathy.  
More recently groups have reported significant associations with 
neuropathy for SNPs in genes that are relevant to taxane pharmacodynamics 
(PD) such as β-Tubulin IIa (TUBB2A)(141) and FANCD2(142), though attempted 
replication of these findings has not been reported. Because our understanding 
of taxane pharmacology and neuropathy etiology is so limited, groups have 
attempted to use a genome-wide approach to discover SNPs that are associated 
with paclitaxel-induced neuropathy risk. The first genome-wide association study 
(GWAS) was published earlier this year by Baldwin et al. Using a large cohort of 
breast cancer patients they identified a single SNP in the FGD4 gene that they 
were able to replicate in two smaller independent patient cohorts(143). 
Preliminary results of one other paclitaxel-induced neuropathy GWAS have been 
reported(108), however, attempted replication of these unpublished SNPs was 
unsuccessful(144).  
Validation of these associations would enable translation into clinical 
practice where they could be used to predict which patients will experience 
neurotoxicity. These patients could be treated with modified taxane regimens or 
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alternative therapies to maximize efficacy while minimizing toxicity. The first step 
in this process, the discovery of these genetic loci, is a formidable task given the 
millions of known polymorphisms, thousands of relevant genes, and our limited 
understanding of taxane pharmacokinetics and pharmacology.   
PERSPECTIVE  
The taxanes are an effective class of chemotherapeutic agents that are 
associated with development of peripheral neurotoxicity. This adverse event 
provokes a great deal of patient suffering and often necessitates discontinuation 
of therapy. Part of the variability in neuropathy risk is explained by differences in 
drug exposure or clinical factors, both of which are likely to be influenced, at least 
in part, by variation in germline genetics. The overall hypothesis of this 
dissertation is that germline variants that modulate a patient’s risk of 
experiencing taxane-induced peripheral neuropathy can be discovered and 
validated using a variety of pharmacogenetic analysis techniques in independent 
cohorts of taxane-treated patients. Despite previous attempts to discover and 
validate genetic loci that modulate risk of taxane-induced neuropathy there are 
critical gaps in our knowledge in this area. Clinical validation of variants could 
improve our understanding of the etiology of taxane-induced peripheral 
neuropathy and more importantly could directly improve patient care by enabling 
identification of patients at high risk of taxane-induced neuropathy who should be 
treated with modified taxane doses or non-taxane containing regimens. 
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SPECIFIC AIMS 
I. Confirm in an independent cohort that patients who carry CYP2C8*3 are at 
increased risk of paclitaxel-induced peripheral neuropathy. 
Hypothesis. Patients from the Lineberger Comprehensive Cancer Center 
(LCCC) 9830 database who carry CYP2C8*3 are at increased risk of 
experiencing grade 2+ peripheral neurotoxicity by a cumulative dose of 
paclitaxel. 
II. Discover and validate variants in genes relevant to drug metabolism, 
elimination, and transport that increase a patient’s risk of experiencing grade 
2+ neuropathy during paclitaxel treatment. 
Hypothesis. Interrogation of variants on the Affymetrix DMET™ Plus Chip in 
Caucasian patients from the LCCC 9830 database will identify variants in 
genes relevant to paclitaxel pharmacokinetics that modulate a patient’s risk of 
experiencing grade 2+ peripheral neurotoxicity during treatment. 
III. Discover variants anywhere in the genome that are associated with modulated 
risk of experiencing grade 3+ neuropathy by a cumulative dose of docetaxel 
through competing-risks analysis and genome-wide association. 
Hypothesis. Competing-risks analysis of all variants on the Illumina 610 Quad 
Chip in genetically-defined European patients from the Cancer and Leukemia 
Group B (CALGB) 90401 study will identify variants that are associated with 
modulated likelihood of experiencing grade 3+ peripheral neurotoxicity during 
treatment with docetaxel.
Hertz DL, Roy S, Motsinger-Reif AA, Drobish A, Clark LS, McLeod HL, Carey LA, 
Dees EC. CYP2C8*3 increases risk of neuropathy in breast cancer patients 
treated with paclitaxel. Annals of Oncology 2013; (In press) 
 
 
CHAPTER II 
CONFIRM IN AN INDEPENDENT COHORT THAT PATIENTS WHO 
CARRY CYP2C8*3 ARE AT INCREASED RISK OF PACLITAXEL-
INDUCED PERIPHERAL NEUROPATHY 
INTRODUCTION 
Paclitaxel is one of the most highly effective therapies in the treatment of 
breast cancer, improving disease free survival when added sequentially to 
anthracycline based combination therapy in the adjuvant setting(145, 146). Many 
patients, however, are unable to tolerate the full course of paclitaxel therapy due 
to the appearance and progression of sensory neurotoxicity. In large trials, the 
rate of grade 2 and higher (grade 2+) sensory neuropathy is 15-20%(146-148). 
Grade 2 neuropathy manifests as a tingling or burning sensation, which can 
progress to paresthesia that interferes with activities of daily living (grade 3 
toxicity)(149). Paclitaxel-induced neuropathy typically resolves over time if 
treatment is discontinued, but may be irreversible beyond a certain level of 
severity(85). For this reason paclitaxel therapy is often discontinued once a 
patient experiences grade 2+ neurotoxicity.  
There are known risk factors for development of paclitaxel-induced 
neuropathy; patients who have prior neuropathy, either from diabetes(150) or 
neurotoxic chemotherapeutic treatment(106), are at increased risk. There also 
may be an increased risk for patients who are older(101) or African-
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American(108), though these associations may reflect some other causal factor. 
The progressive nature of paclitaxel-induced neuropathy suggests toxicity 
development may be attributed to cumulative drug exposure. Indeed, increased 
cumulative dose(90) and an increase in the time that the drug concentration 
remains above a threshold for a given dose(95) are both associated with 
increased neuropathy risk. 
Paclitaxel is primarily metabolized by CYP2C8(22), with a contribution 
from CYP3A4(23), and exposure to paclitaxel in cancer patients is correlated with 
CYP2C8 activity(151) (Appendix 2). Thus, any factor which modulates the 
activity of CYP2C8 is likely to influence the patient’s exposure to paclitaxel. 
Fortunately, CYP2C8 has few inhibitors and inducers with which paclitaxel would 
have drug interactions. Despite the relative lack of interactions, there is still 
appreciable inter-patient variability (19-26%) in clearance of unbound paclitaxel 
left unexplained after accounting for baseline factors such as body size and 
bilirubin(45).  
Some common single nucleotide polymorphisms (SNPs) in the CYP2C8 
gene yield changes in amino acid sequence. CYP2C8*3, the most common 
variant found in European individuals, refers to two non-synonymous exonic 
SNPs (rs11572080 Arginine139Lysine (R139K), and rs10509681 Lysine399 
Arginine (K399R)) which are very often co-inherited. However, in some 
individuals only the K399R mutation is found(152). Based on in vitro data the 
K399R amino acid substitution is responsible for the change in enzyme activity; 
only this variant demonstrates decreased paclitaxel metabolism when each are 
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tested in isolation(153, 154). It was recently reported that patients carrying the 
K399R variant exhibit decreased clearance of the free parent compound, and 
increased overall exposure(155).   
Gréen et al. were the first to suggest a potential increase in neuropathy 
risk for patients who carried the CYP2C8*3 variant(131). We recently reported 
results from a small pharmacogenetic study demonstrating that breast cancer 
patients treated with neoadjuvant paclitaxel who carried the *3 allele were more 
likely to achieve clinical complete response from paclitaxel treatment (55% 
versus 23%; OR=3.92, 95% CI: 1.46-10.48, corrected p=0.046), but tended to 
have higher incidence of grade 3+ neuropathy (22% vs. 8%; OR=3.13, 95% CI: 
0.89-11.01, uncorrected p=0.075)(133) (Appendix 1). Leskela et al. also 
detected a significant increase in risk of experiencing neuropathy in patients who 
were homozygous for the *3 allele(132). Therefore we hypothesized that these 
findings could be replicated in a larger, independent cohort of European-
American breast cancer patients treated with paclitaxel, then replicated again in a 
cohort of African-American patients.  
METHODS 
Patients and Treatments   
CYP2C8*3 K399R (referred to as CYP2C8*3 from now on) was genotyped 
in a cohort of patients treated between 2005 and 2011 and derived from the 
University of North Carolina Lineberger Comprehensive Cancer Center (UNC 
LCCC) Breast Cancer Database, which includes prospective collection of 
demographic data, including self-reported race, treatment details, and toxicities. 
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Eligible women received neoadjuvant and/or adjuvant paclitaxel-containing 
regimens and enrolled in an IRB approved clinical trial that collected genomic 
DNA from all newly diagnosed patients. In most cases patients received 
paclitaxel on a familiar neoadjuvant or adjuvant treatment protocol, with a 
predefined dose, schedule, and duration. Some patients received treatment 
concurrent with paclitaxel, most commonly with a biological agent for HER2 over-
expressing tumors. Toxicities were evaluated during paclitaxel treatment, 
recorded prospectively, and coded by National Cancer Institute Common 
Terminology Criteria for Adverse Events (NCI CTCAE) based on the physician’s 
description(149). Use of supplemental neuropathy prevention (glutamine, vitamin 
B complex, or vitamin B6) or treatment (gabapentin or amitriptyline) was at the 
discretion of the treating clinician and prospectively recorded. All patients signed 
informed consent to participate and agreed to allow DNA to be collected for 
additional pharmacogenetic studies. The study protocol was approved by the 
UNC Institutional Review Board.  
SNP Genotyping 
A 30 mL blood sample was collected from each subject at the time of 
study enrollment. DNA used for genotyping was extracted by the UNC 
Biospecimen Processing Facility and plated at 60 ng/uL. Genotyping was carried 
out blinded to clinical data using the Affymetrix DMET™ Plus Chip (Affymetrix, 
Inc., Santa Clara, CA, USA) at Gentris Corp. (Gentris Corp. Morrisville, NC) 
following the manufacturer’s protocol with known genomic DNA controls provided 
by Affymetrix to monitor inter- and intra-assay performance. Any sample or assay 
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with call rate <98% was excluded from analysis. CYP2C8*3 K399R (rs10509681) 
(AM_10125) was the only SNP analyzed for this replication study; all non-*3 loci 
are assumed to be wild-type (*1) enabling classification of every subject as 
CYP2C8*3 variant (*3/*3), heterozygote (*1/*3), or wild-type (*1/*1).    
Statistical Analysis 
The primary analysis was carried out in a cohort of self-reported 
European-American patients who were not included in the previous 
analysis(133). African-American patients were analyzed separately in a cross-
race replication. These two groups were then combined with patients of other 
races and previously reported patients to create a large mixed-race cohort. 
CYP2C8*3 was assessed for concordance with Hardy-Weinberg Equilibrium 
(HWE) using Fisher’s exact test. The primary toxicity endpoint was the 
cumulative paclitaxel dose at which grade 2+ neuropathy was first reported and 
any patient not experiencing grade 2+ toxicity was censored at their cumulative 
dose received. The primary analysis plan was to use the log-rank test to 
determine whether there is a difference in risk of grade 2+ neuropathy across 
European-American patients classified by CYP2C8*3 K399R genotype. A 
standard α=0.05 was utilized due to the single SNP-phenotype association tested 
in the primary analysis.  
Secondary analyses with grade 2+ or 3+ neurotoxicity incidence, without 
consideration of dose, were carried out using a Fisher’s Exact test across the 3 
genotype groups (*1/*1, *1/*3, *3/*3). Following log-rank analysis additional 
covariates (age [continuous variable], prior diagnosis of diabetes [yes vs. no], 
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taxane schedule [80-90mg/m2 weekly vs. 175mg/m2 every 2 or 3 weeks], use of 
prophylactic or therapeutic neuropathy treatment [yes vs. no]) were included in a 
multiple Cox proportional hazards model to adjust for their potential influence on 
neuropathy risk. Backward selection using Akaike Information Criteria (AIC) as a 
selection criterion was used to select the final model. AIC balances model 
goodness of fit and complexity by penalizing the inclusion of extra covariates; it 
has been shown to be an effective model selection tool(156). Replication of 
positive findings in the European-American cohort was attempted via log-rank 
analysis in the self-reported African-American patients. Finally, the entire patient 
cohort was analyzed in a multiple Cox proportional hazards model which 
included self-reported race (European vs. Non-European) in addition to the 
previously described covariates. All statistical analyses were carried out in R 
Statistical Software, version 2.13.0 (R Development Core Team, Vienna, 
Austria). 
RESULTS 
Patient Population 
411 paclitaxel treated patients were eligible for analysis and successfully 
genotyped for CYP2C8*3 by DMET™ Plus. Demographic data including patient 
and treatment characteristics for the European-American (N=209), African-
American (N=107), and a combined, mixed-race cohort (N=411) can be found in 
Table 1.  
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CYP2C8*3 
The distribution of the CYP2C8*3 variant conformed to Hardy-Weinberg 
Equilibrium separately in the European-American (p=0.79) and African-American 
(p=0.77) cohorts(157). Allele frequency (AF) in the European- (AF=0.14) and 
African- (AF=0.03) American patients were consistent with that previously 
reported for each reference population in the International Hapmap Project : CEU 
(Utah residents with Northern and Western European ancestry) AF=0.14 and 
ASW (African Ancestry in Southwest USA) AF=0.04, respectively(158, 159). The 
number of *1/*1, *1/*3, and *3/*3 women in each cohort is displayed in Table 1 
along with the frequencies of grade 2+ (17%-21%) and grade 3+ (8-14%) 
neuropathy, which were similar to those reported in prior paclitaxel studies(146-
148).  
 
Neuropathy by Genotype 
Analysis in European-American cohort 
In the primary analysis the log-rank test demonstrated a difference in risk 
of grade 2+ neuropathy across genotype groups, as displayed in the Kaplan-
Meier curves in Figure 1. As expected, risk of neuropathy was highest in patients 
who were homozygous for the *3 variant and lowest in patients homozygous for 
the wild-type allele (log-rank p=0.006). The hazard ratio for the *3 homozygotes 
vs. other individuals (*3/*3 vs. *1/*3 & *1/*1, recessive genetic model) was 
statistically significant (Hazard Ratio(HR)=7.16, 95% Confidence Interval (95% 
CI): 1.70-30.17, p=0.002). Assuming an additive effect for each *3 variant an 
 21 
 
individual carries (0, 1, or 2) also gave significant results (HR=1.93, 95% CI: 
1.05-3.55, p=0.032) but the hazard ratio for comparing carriers of the *3 variant 
vs. the wild-type homozygotes (*3/*3 & *1/*3 vs. *1/*1: dominant genetic model) 
was not statistically significant (HR=1.74, 95% CI: 0.88-3.45, p=0.110). In the 
secondary analysis, which did not account for cumulative dose, the incidence of 
grade 2+ neurotoxicity differed across the three genetic groups (Variant: 67%, 
Heterozygote: 22%, Wild-type: 14%, p=0.042) while the results from the grade 3+ 
analysis were consistent in trend but did not reach significance (p=0.313, data 
not shown).  
 Clinically relevant covariates: age, prior diabetes diagnosis, use of 
neuropathy prophylaxis or treatment, and paclitaxel schedule, were included in a 
multiple Cox proportional hazards model. The only covariate that was kept in the 
backwards selection procedure was diabetes history (Table 2). Similar to the 
unadjusted analysis, in the final model the association between CYP2C8*3 
genotype and risk of grade 2+ neuropathy was significant assuming a recessive 
(HR = 6.88, 95% CI: 1.62-29.14, p=0.009) or additive (HR=1.95, 95% CI: 1.06-
3.58, p=0.031), but not a dominant (HR = 1.77, 95% CI: 0.89-3.52, p = 0.102), 
genetic effect.   
Replication in African-American Cohort   
107 self-reported African-American individuals were evaluable in the 
cross-race replication. As expected the variant allele was substantially less 
common in this cohort (AF=0.03) and there were no *3 homozygous individuals. 
Comparing patients carrying one CYP2C8*3 allele with wild-type homozygous 
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patients again showed greater risk of grade 2+ peripheral neuropathy in the log-
rank analysis (HR=3.30, 95% CI:1.04-10.45, p=0.043) and a trend in the same 
direction using the Fisher’s exact test (50% vs. 20%, p=0.112) (Figure 2).  
Cox Proportional Hazards Model in Mixed-Race Cohort  
411 paclitaxel treated women were available for inclusion in a Cox 
proportional hazards model that included self-reported race (European vs. non-
European). In the final model there was a higher risk of grade 2+ neuropathy in 
non-European women (HR=1.76, 95%CI: 1.05-2.93, p=0.031) (Figure 3) and a 
non-significant, negligible increase in risk as patient age increases (HR=1.02, 
95% CI: 1.00-1.04, p=0.102) (Table 2). After adjustment for these covariates the 
association between increased risk of grade 2+ neuropathy and CYP2C8*3 was 
significant (Figure 4) in either a dominant (HR = 2.04, 95% CI: 1.21-3.43, 
p=0.007) or additive genetic model (HR = 1.98, 95% CI: 1.25-3.13, p=0.004) but 
not in a recessive model (HR = 3.41, 95% CI: 0.82-14.16, p=0.092). In follow-up 
exploratory model building an interaction between race and diabetes history was 
discovered, in which a diagnosis of diabetes increased risk of neuropathy in 
European patients but decreased risk in non-European patients (p=0.029, Figure 
5).  
DISCUSSION 
CYP2C8*3 had been previously suggested as a risk factor for increased 
neuropathy occurrence in breast cancer patients treated neoadjuvantly with 
paclitaxel(133) (Appendix 1). In that exploratory toxicity analysis within an 
efficacy study, the data and cohort were not optimized for the neuropathy 
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endpoint. Only grade 3+ toxicities were considered and the cumulative dose 
received at the time of toxicity was not accounted for. Also, because there were 
other variants besides CYP2C8*3 being interrogated, and the cohort was 
relatively small, the analysis was not stratified by race a priori. Despite these 
limitations a trend was discovered for greater grade 3+ neuropathy incidence in 
patients carrying the CYP2C8*3 variant (Odds ratio (OR)=3.13, 95% CI: 0.89-
11.01, uncorrected p=0.075). Based on this exploratory finding, and two 
previously published concurring studies, we attempted to replicate the 
association in two independent cohorts from the same database, and then 
combined these replication sets with other available patients to more 
comprehensively investigate this association.  
The current study provides replication of an association between the 
CYP2C8*3 K399R variant and increased risk of grade 2+ paclitaxel-induced 
neuropathy in European-American patients. The association was then replicated 
separately in the African-American patients. Finally, a model was built that 
included all patients and relevant clinical covariates, and after adjusting for race, 
age, and diabetes, the risk of grade 2+ neuropathy was greater in women 
carrying CYP2C8*3.  
Leskela et al. previously reported that CYP2C8*3 increased risk of 
paclitaxel-induced neuropathy(132). Their study was carried out in a cohort of 
Spanish paclitaxel-treated cancer patients with dose-to-grade 2+ neuropathy 
used as the primary endpoint and taxane schedule and patient age adjusted for. 
Our analysis plan, endpoints, and covariates were similar to theirs and our 
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results confirm their findings. Although they assumed an additive model, their 
data suggested that a recessive effect may best characterize the influence of the 
*3 variant. The results from our European-American cohort also suggested a 
recessive model but the results in the larger mixed-race cohort are significant 
with either the dominant or additive model. Indeed, the approximate doubling of 
risk associated with the addition of each *3 allele, found both by Leskela et al. 
and us, suggests an additive genetic effect may be most appropriate.   
While the association between CYP2C8*3 and paclitaxel-induced 
neuropathy has now been replicated multiple times, there are previous reports 
which did not demonstrate this association(134-137). Differences in patient 
inclusion, study design, and end point likely explain these discrepant findings, 
similar to that seen with other inconsistently demonstrated pharmacogenetic 
associations(160). Specifically, one study combined patients on either paclitaxel 
(24%) or docetaxel (76%) and analyzed these groups together(135). While 
docetaxel has both structural and mechanistic similarity to paclitaxel, it has a 
lower incidence of neurotoxicity and is not metabolized by CYP2C8. The other 
three studies utilized patient cohorts that were treated concomitantly with 
carboplatin. Carboplatin is less neurotoxic than other platinum compounds but is 
known to induce sensory neuropathy(161). Neuropathy risk from docetaxel or 
carboplatin would not be modulated by CYP2C8, thus confounding these 
previous analyses. In the present study all patients were treated with paclitaxel 
and only 22% received concurrent treatment, the vast majority of which was non-
neuropathic biological treatment (bevacizumab, trastuzumab, lapatinib); only five 
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patients (1.2%) were concurrently treated with a drug associated with neuropathy 
(carboplatin). Moreover, patients who received treatment prior to paclitaxel (78%) 
received almost exclusively doxorubicin/cyclophosphamide (98%), which is not 
neurotoxic, and only one patient was previously treated with a known neurotoxin 
(docetaxel) (Table 1).   
Hapmap reference populations indicate that the *3 variant is not found in 
patients of African descent (Yoruban in Ibadan, Nigeria [YRI] AF=0.00), however, 
the allele frequency in our African-American patients (AF=0.03) was very similar 
to that reported for individuals of African ancestry living in the United States 
(ASW AF=0.04), corroborating past reports that African-American patients harbor 
varying amounts of European and African genetic loci(162) (Figure 6). Based on 
our findings, not only is the *3 variant found in individuals from a wide range of 
self-reported races, the increase in neuropathy risk it confers is consistent across 
racial groups.   
Despite the lower frequency of the high risk variant in non-European 
individuals, these patients were at an increased risk of neuropathy overall 
(HR=1.76, 95% CI: 1.05-2.93, p=0.031). This finding confirms a recent 
publication from Schneider et al.(109) and suggests that while CYP2C8*3 is one 
factor that influences a patient’s risk of paclitaxel-induced neuropathy, perhaps 
along with age and diabetes history, there are other currently unappreciated 
factors at work. An inter-race difference in paclitaxel exposure is possible, but to 
our knowledge this has never been reported and does not exist with 
docetaxel(163), which again is not metabolized by CYP2C8. It is noteworthy that 
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the risk of HIV-associated distal neuropathy(164) and diabetes-related 
neuropathy(165) are greater in African-Americans than European-Americans; 
thus there seems to be a general predisposition to neuropathy in African-
Americans regardless of etiology. We hypothesize that there are inter-race 
differences in frequencies of genetic loci responsible for this phenotype that are 
not currently known. We also identified an unexpected interaction between race 
and diabetes in which diabetes history increased neuropathy risk in Europeans 
but decreased risk in non-Europeans, which caused diabetes history to be 
eliminated from the final Cox model in the mixed race cohort. However, this 
finding may be merely a statistical artifact secondary to testing many interactions 
in exploratory model building in a relatively small number of diabetic individuals 
(n=48, Figure 5).  
The major limitation of this study is the retrospective use of a clinical 
registry instead of a prospective clinical study. This manifests in a number of 
ways, most notably the differences in paclitaxel treatment and schedule, the use 
of neuropathy prophylaxis or treatment, and the non-uniformity in toxicity 
collection. We have attempted to adjust for these factors when possible. In meta-
analyses comparing the risk of neuropathy for the weekly vs. 3-weekly 
schedules, the dose intensity was found to be a more important factor than 
schedule itself(100). The patients in this analysis were treated with one of three 
standard paclitaxel regimens: 3-hour infusion of 175 mg/m2 every three weeks 
(58.3 mg/m2/wk) or every two weeks (87.5 mg/m2/wk) or a 1-hour weekly infusion 
(80-90 mg/m2/wk). Despite attempts to include this data in Cox models, we could 
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not detect a significant influence on neuropathy risk for paclitaxel dose, schedule, 
or infusion time, all of which are highly collinear in this dataset.  
Use of supplementary agents to prevent or treat neuropathy was 
somewhat common in this patient cohort (35%, Table 1). The majority of these 
patients (78%) received the non-FDA approved amino-acid supplement 
glutamine, which has shown inconsistent efficacy in clinical studies(166, 167). 
Perhaps due to differences in effectiveness of the various agents administered, 
or the timing of neuropathy development and supplement use, we did not see an 
association with the risk of neuropathy.  
The neuropathy data was collected and recorded by the treating 
oncologist or nurse at each treatment visit. This relies on patient reporting, as no 
validated measure of sensory neuropathy is used consistently in outpatient 
paclitaxel treatment(168). Though this may limit the accuracy of data collection, 
relative to a validated test performed at pre-specified times during therapy, the 
treating clinician’s decision to switch drugs, delay treatment, or decrease the 
dose also relies on patient reports, thus clinically relevant toxicities will be 
captured by this method. The use of grade 2+ neuropathy, the severity at which 
alternative treatment strategies are considered, improved our study power by 
approximately doubling our event rate as compared to using grade 3+ toxicity, 
and avoided the possible confounding of patients discontinuing treatment when 
grade 2 neuropathy is encountered. Moreover, because grade 2 neurotoxicity 
often progresses to grade 3, it is clinically useful to identify patients at risk of 
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experiencing grade 2+ neuropathy before therapy is initiated, and analyses with 
this endpoint are free of the confounding present in assessing grade 3+ toxicity. 
We have previously reported that patients carrying the *3 variant 
experience superior clinical response from paclitaxel treatment, consistent with 
the demonstrated correlation between paclitaxel exposure and treatment 
efficacy(39, 169). This apparent shift of the therapeutic window suggests that the 
optimal dose of paclitaxel may need to be stratified in the general population 
based on CYP2C8*3 status, similar to a recent Phase I study which identified 
maximum tolerated irinotecan doses based on the patient’s UGT1A1*28 
genotype(123). Further work with population pharmacokinetic models that 
account for key patient factors in addition to CYP2C8 genotype(155, 170) may 
enable appropriate dose selection for a patient, bypassing stratified therapy and 
realizing truly individualized therapy. 
In conclusion, we have replicated a previous finding that CYP2C8*3 
carriers are more likely to experience sensory peripheral neuropathy when 
treated with paclitaxel in two racially homogenous populations. This association 
remained significant after adjustment for clinical covariates that are thought to 
modify risk of neuropathy; age, treatment schedule, and diabetes. In our mixed-
race cohort the risk of neuropathy doubled for a *3 homozygote compared to a 
heterozygote and a heterozygote compared to a wild-type homozygous patient, 
suggesting an additive or gene-dose effect. Although the *3 variant is less 
commonly found in non-European individuals, the increased risk of paclitaxel-
induced neuropathy is consistent across racial groups. Future work should focus 
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on translating these findings to optimize paclitaxel dosing so that patients 
achieve the greatest possible therapeutic benefit with an acceptable risk of 
severe toxicity. 
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TABLES 
Table 1 Characteristics of LCCC 9830 CYP2C8*3 Patient Cohort 
  
European-
American 
African-
American 
Mixed-Race  
(n=411) 
Age (Years)  
Median 51  46 50 
Range  24-84 25-68 22-84 
Self-
reported 
Race 
European 209 0 287 
African-American 0 107 107 
Other 0 0 17 
Neuropathy  
Grade 2+ 35 (17%) 23 (21%) 76 (18%) 
Grade 3+ 16 (8%) 15 (14%) 42 (10%) 
CYP2C8*3 
(K399R) 
Genotype^ 
Wild-type (*1/*1) 155 (74%) 101 (94%) 330 (80%) 
Heterozygous (*1/*3) 51 (24%) 6 (6%) 76 (18%) 
Variant (*3/*3) 3 (1%)  0 5 (1%) 
Treatment 
Prior to 
Paclitaxel 
AC (Doxorubicin/Cyclophos) 154 (74%) 87 (81%) 316 (77%) 
AC + Bevacizumab 2 0 2  
A (Doxorubicin) 2 0 2 
AC + Docetaxel 1 0 1 
Treatment 
Concurrent 
to Paclitaxel  
Trastuzumab 33 (16%) 21 (20%) 71 (17%) 
Bevacizumab 4 (2%) 4 (4%) 9 (2%) 
Carboplatin 1 1 2 
Carboplatin + Bevacizumab 1 2 3 
Trastuzumab + Lapatinib 4 0 4 
Trastuzumab + Cyclophos. 0 0 1 
Paclitaxel 
Schedule & 
Dose   
80-90 mg/m
2
 Weekly 64 (31%) 34 (32%) 131 (32%) 
175 mg/m
2
 Every 2 weeks  130 (62%) 64 (60%) 235 (57%) 
175 mg/m
2
 Every 3 weeks 15 (7%) 9 (8%) 45 (11%) 
Total 
Paclitaxel 
Received 
Median (mg/m
2
) 700 700 700 
Range (mg/m
2
) 80-1280 160-1280 80-1280 
Diabetes  
Prior diagnosis 16 (8%) 24 (22%) 48 (12%) 
No prior diagnosis 193 (92%) 83 (78%) 363 (88%) 
Neuropathy 
Prophylaxis 
or 
Treatment  
Gabapentin 6 (3%) 7 (7%) 15 (4%) 
Amitriptyline 5 (2%)  1 9 (2%) 
Glutamine 62 (30%) 22 (21%) 112 (27%) 
Vitamin B Complex 1  0 1 
Vitamin B6 4 (2%) 2 7 (2%) 
Total 78 (37%) 32 (30%) 144 (35%) 
Treatment 
Modality^ 
Neoadjuvant 58 (28%) 47 (44%) 188 (46%) 
Adjuvant 153 (73%)** 61 (57%)** 226 (55%)** 
^: Differences due to known allele frequency differences between races.  
**: Three patients were treated with paclitaxel neoadjuvantly and adjuvantly   
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Table 2 Cox Proportional Hazards Model for Grade 2+ Neuropathy 
 European Cohort (n=209) Mixed-race Cohort (n=411) 
 Hazard 
Ratio 
95% 
Confidence 
Interval 
P-value Hazard 
Ratio 
95% 
Confidence 
Interval 
P-value 
CYP2C8^  
*1/*3 vs. *1/*1 
1.55 0.75-3.21 0.234 1.95 1.14-3.32 0.015* 
CYP2C8^  
*3/*3 vs. *1/*3 
5.01 1.09-23.02 0.038* 2.14 0.50-9.27 0.307 
CYP2C8^  
*3/*3 vs. *1/*1  
7.78 1.80-33.62 0.004* 4.17 0.99-17.60 0.052 
Diabetes 
Diagnosis  
2.18 0.84-5.63 0.110 Not included in final model 
Age  
 
 Not included in final model 1.02 1.00-1.04 0.102 
Self-Reported 
Race**  
No racial heterogeneity 1.76  1.05-2.93 0.031* 
^CYP2C8 comparisons are made between individual genotype groups, not based 
on assumptions of genetic effect (recessive, additive, or dominant). 
*Statistically Significant Difference 
**Non-European-American (African-American + Other) vs. European-American 
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FIGURE LEGENDS 
 
Figure 1 Incidence curve for grade 2+ neuropathy across genotype groups in the 
European cohort (n=209). The highest risk was seen in the variant homozygotes 
and the lowest risk in the wild-type homozygotes.  
 
Figure 2 Incidence curve for grade 2+ neuropathy across genotype groups in the 
African-American replication cohort (n=107). Higher risk was seen in the carriers 
of the CYP2C8*3 variant homozygotes as compared to the wild-type 
homozygotes (p=0.043). No homozygous variant individuals were found in this 
cohort. 
 
Figure 3 Incidence curve for grade 2+ neuropathy across racial groups in the 
entire mixed-race cohort (n=411). Higher risk was seen in the non-European-
American (n=124) as compared to the European-American (n=287) women after 
adjusting for CYP2C8 and age (p=0.031).  
 
Figure 4 Incidence curve for grade 2+ neuropathy across genotype groups in the 
mixed-race cohort (n=411). This data indicates that each *3 variant 
approximately doubles a patient’s risk of grade 2+ neuropathy, supporting an 
additive genetic effect. 
 
Figure 5 Incidence curve for grade 2+ neuropathy for the entire patient cohort 
(n=411) stratified by race and diagnosis of diabetes. Risk of neuropathy 
 33 
 
increased in European patients with diabetes but decreased for non-European 
patients.  
 
Figure 6 Principal components analysis of DMET™ genotype data for entire 
cohort (N=411, circles) and reference Hapmap populations (triangles): CEU 
(Utah residents with Northern and Western European ancestry), CHB (Han 
Chinese in Beijing, China), JPT (Japanese in Tokyo, Japan), and YRI (Yoruban 
in Ibadan, Nigeria). The self-reported white patients (orange circles) 
predominantly cluster with the European Hapmap samples (orange triangles). 
The self-reported black patients (red circle) cluster near the Hapmap African 
samples (red triangles) however; they are shifted toward the Europeans 
demonstrating that genetically they represent a continuum between the two 
groups. Some self-reported white individuals don’t cluster with the European 
samples, but instead cluster with the black patients or fall between the European 
and Asian samples while some self-reported black patients cluster with the 
European samples. 9830 Patients who reported their ethnicity as ‘other’ (blue 
circles) are a mixture of Asians, who cluster with the Asian Hapmap samples 
(green and purple triangles), Hispanics, American Indians, and other ethnicities.  
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FIGURES 
Figure 1 Neuropathy by CYP2C8 Genotype in LCCC 9830 Europeans 
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Figure 2 Neuropathy by CYP2C8 Genotype in LCCC 9830 African-Americans
 
 
  
 36 
 
Figure 3 Grade 2+ Neuropathy Incidence by Race in LCCC 9830
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Figure 4 Neuropathy by CYP2C8 Genotype in LCCC 9830 Cohort
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Figure 5 Neuropathy Incidence Stratified by Race and Diabetes 
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Figure 6 Principal Components Analysis of LCCC 9830 Patients with Hapmap 
Controls 
Daniel L. Hertz, Siddharth Roy, Alison A. Motsinger-Reif, Amy Drobish, L. Scott 
Clark, Howard L. McLeod, Lisa A. Carey, E. Claire Dees. Affymetrix DMET™ 
Plus Chip Identifies SNP in ABCG1 that Modulates Risk of Paclitaxel-Induced 
Neuropathy in Caucasians  
 
 
 
CHAPTER III 
DISCOVER AND VALIDATE VARIANTS IN GENES RELEVANT TO 
DRUG METABOLISM, ELIMINATION, AND TRANSPORT THAT 
INCREASE A PATIENT’S RISK OF EXPERIENCING GRADE 2+ 
NEUROPATHY DURING PACLITAXEL TREATMENT  
INTRODUCTION 
In breast cancer treatment, the sequential addition of paclitaxel to 
standard anthracycline therapy has improved rates of pathological complete 
response in neoadjuvant treatment(171) and overall survival in the adjuvant 
setting(145, 146). Along with its impressive efficacy, paclitaxel treatment is 
associated with a variety of severe adverse events, including the development of 
peripheral sensory neuropathy which typically presents as tingling in the fingers 
and toes that will often resolve if treatment is discontinued(85). However, mild 
neuropathy will progress with continued treatment to potentially irreversible loss 
of tactile function and balance(84).  
Neuropathy development is partly determined by the cumulative paclitaxel 
dose administered over the course of therapy(85, 90-93), and may also depend 
in part on the exposure to a given dose(95). Patients who carry the CYP2C8*3 
variant experience greater exposure to paclitaxel than wild-type homozygous 
individuals(155) and are at increased risk of paclitaxel-induced neuropathy(132, 
133)(Chapter 2). In addition to CYP2C8, there are a number of enzymes(23) and 
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transporters(20, 26, 36) known to be involved in paclitaxel pharmacokinetics. 
Variability in the activity of these enzymes and transporters may also contribute 
to variability in paclitaxel exposure and consequently modify the risk of paclitaxel-
induced neuropathy. 
  Many prior studies have investigated whether there is an association 
between variants in these candidate genes and risk of neuropathy(132, 134, 137, 
139, 141, 142, 172-175), however, none have accounted for the underlying 
influence of CYP2C8*3 or used an approach that can comprehensively and 
directly interrogate thousands of variants that are most likely to influence 
paclitaxel exposure. The Affymetrix (Santa Clara, CA) DMET™ Plus Chip is a 
commercially available genotyping panel that interrogates nearly 2,000 genetic 
variants within genes that are responsible for Drug Metabolism, Elimination, and 
Transport (DMET™)(176). We hypothesized that using the DMET™ Plus Chip to 
further genotype a cohort of patients who have previously been analyzed 
specifically for the CYP2C8*3 variant, we could identify additional genetic loci 
that influence a patient’s risk of paclitaxel-induced neuropathy. By conditioning 
our analysis on CYP2C8*3, we can eliminate the known effect of this variant and 
more directly investigate the genetic sources of the remaining variability, 
potentially validating prior results from candidate gene studies or discovering 
genes not previously recognized to influence the risk of paclitaxel-induced 
neuropathy.   
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METHODS 
Patients and Treatments  
The subjects, toxicity, and covariate data for this analysis were the same 
as those used in Chapter 2. The primary analysis for this aim was restricted to 
the self-reported Caucasian patients; all non-Caucasian patients were included in 
a secondary cohort for potential replication. The study protocol was approved by 
the UNC Institutional Review Board.  
Genotyping 
A 30 mL blood sample was collected from each subject at the time of 
study enrollment. DNA used for genotyping was extracted by the UNC 
Biospecimen Processing Facility and plated at 60 ng/uL. Genotyping was carried 
out blinded to clinical data using the Affymetrix DMET™ Plus Chip (Affymetrix 
Inc., Santa Clara, CA, USA) at Gentris Corp. (Gentris Corp. Morrisville, NC) 
following the manufacturer’s protocol with known genomic DNA controls provided 
by Affymetrix Inc. to monitor inter- and intra-assay performance. Any patient 
sample or assay with successful call rate <95% or <90%, respectively, was 
excluded from analysis. Variants were also excluded if the minor allele frequency 
was <5% in the entire population or if the p-value for the Fisher’s Exact estimate 
of Hardy-Weinberg proportions was <0.05 in either the Caucasian or non-
Caucasian cohort.       
Statistical Analysis 
The primary toxicity endpoint was the incidence of grade 2+ neuropathy 
during paclitaxel treatment (Yes vs. No). Exact testing, conditioned on previously 
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analyzed results for the CYP2C8*3 (K399R, rs10509681) variant, was used to 
compare the risk of neuropathy incidence across genotype groups for each 
marker that passed quality control. Due to the exploratory nature of this study, 
uncorrected p-values were compared with a significance threshold α=0.001 
which was selected for consistency with prior pharmacogenetic discovery studies 
utilizing the DMET™ Plus Chip(177).  
Variants that surpassed the exploratory significance threshold were tested 
in a log-rank analysis utilizing the dose-at-onset of grade 2+ neuropathy in order 
to account for the known effect of cumulative paclitaxel treatment. Any patient not 
experiencing grade 2+ neuropathy was censored at the cumulative dose they 
were administered over the course of therapy. Variants with significant findings in 
the dose-to-event analysis were then tested in a cross-race replication in the 
non-Caucasian subjects (n=124). Finally, covariates that are thought to be 
relevant to neuropathy risk including: age (continuous), race (Caucasian vs. non-
Caucasian), paclitaxel dose and schedule (80-90mg/m2 weekly vs. 175mg/m2 
every 2-3 weeks), diabetes (yes vs. no), and supplemental neuropathy treatment 
(as defined in the methods above, yes vs. no) were tested in a multiple Cox 
proportional hazards model with backward elimination via AIC to identify only 
those covariates that significantly contributed to model performance. All statistical 
analyses were carried out in R Statistical Software, version 2.13.0 (R 
Development Core Team, Vienna, Austria). 
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RESULTS 
Patient Population  
After exclusion of patients whose samples failed genotyping, 288 
Caucasian paclitaxel-treated patients were included in the primary analysis and 
124 non-Caucasians were evaluable in the replication cohort. Demographic data 
including patient and treatment characteristics for the primary and replication 
cohorts can be found in Table 3. Overall 71 patients experienced grade 2+ 
neuropathy during paclitaxel treatment (71/412=18%) which is consistent with 
other studies of paclitaxel treatment in breast cancer(146). 
DMET™ Markers  
Of the 1,936 genetic markers on the DMET™ Plus chip, a total of 1,372 
were excluded from analysis. 1,275 markers were excluded for minor allele 
frequency <0.05, which is consistent with previously reported DMET™ marker 
allele frequencies in primarily Caucasian cohorts(177). 30 markers were 
excluded from the analysis for call rate <90% and 67 were eliminated for 
significant deviation from Hardy-Weinberg proportions. Thus after appropriate 
quality control 564 markers (29.1%) were included in the analysis.  
Neuropathy by Genotype 
Results of the exact tests conditioned on CYP2C8*3 for the 10 markers 
with the strongest association with neuropathy incidence are displayed in Table 
4, including one marker that surpassed the exploratory significance threshold 
(α=0.001). This was an intronic SNP in ABCG1 (rs492338, uncorrected  
p=0.0008). A contingency table of neuropathy by genotype for the 285 Caucasian 
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patients with genotype calls at this locus is presented in Table 3, exhibiting 
increased neuropathy risk for the minor (T) allele.  
  The results of the secondary analysis using the cumulative dose-at-onset 
of neuropathy were not meaningfully different from the primary findings (HR(per 
allele)=2.11, 95% CI: 1.36-3.29, p=0.0008, Figure 7). In the cross-race 
replication in non-Caucasian patients, rs492338 was not significantly associated 
with grade 2+ neuropathy in either the Fisher’s exact (p=0.60, data not shown) or 
log-rank analysis (p=0.54, Figure 8). We attempted to adjust for covariates of 
interest: age, race, diabetes, taxane schedule, and supplemental neuropathy 
therapy in the entire patient cohort, however, none of the clinical covariates 
survived backward elimination when included with rs492338 in a multiple Cox 
proportional hazards model (data not shown). Finally, the results of this analysis 
were not meaningfully influenced by the conditioning for CYP2C8*3; re-running 
the primary analysis in the Caucasian cohort unconditioned had a negligible 
impact on the Fisher’s Exact p-values of the top 10 hits (Table 4). 
DISCUSSION 
Paclitaxel-induced peripheral neuropathy is known to be dependent on 
drug exposure. Within this patient population we previously demonstrated that 
patients’ who carry the low-activity CYP2C8*3 variant are at increased risk of 
neurotoxicity. We have attempted in the present study to identify germline 
variants that influence risk of neuropathy through a direct effect on drug PK, 
beyond that of CYP2C8*3. In order to do so we used the Affymetrix DMET™ 
Plus chip to simultaneously interrogate up to 1,936 genetic variants within 225 
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genes that encode for the proteins responsible for Drug Metabolism, Elimination, 
and Transport (DMET)(176). This chip has been previously used to identify 
genetic variants that influence treatment outcomes from various other drugs used 
in cancer(178-181) and other diseases(181, 182). 
Despite the use of a genotyping platform that comprehensively 
interrogates markers relevant to drug pharmacokinetics, the only hit that 
surpassed our exploratory significance threshold is located in a gene (ABCG1) 
not thought to be involved in paclitaxel PK. ABCG1 is an intracellular sterol 
transporter that is primarily recognized for its role in regulation of intracellular 
cholesterol levels, particularly in cholesterol-laden macrophages(183). ABCG1 is 
also expressed in peripheral neurons(184) where cholesterol is converted to 
pregnenolone, a reaction that is inhibited by paclitaxel in vitro(185). 
Pregnenolone is then metabolized to progesterone, 5α-dihydroprogesterone, and 
allopregnanolone, which are referred to as neuroactive steroids(186). 
Neuroactive steroids are key regulators of Schwann cell proliferation and myelin 
formation(187); processes initiated in response to axonal demyelination, a 
prominent finding in paclitaxel-induced neurotoxicity both in vitro(188) and in 
vivo(81). Interestingly, co-treatment with neuroactive steroids enhances recovery 
from docetaxel-induced neuropathy in rats(189).  
Several groups have investigated whether SNPs in genes relevant to 
paclitaxel pharmacokinetics are associated with risk of neurotoxicity. None of the 
significant findings from these previous candidate studies, including SNPs in 
CYP3A5(132) and ABCB1(139), reached statistical significance in  our study, so 
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their influence on paclitaxel-induced neuropathy risk could not be verified. 
Attempts to discover loci that modulate risk of paclitaxel-induced neuropathy on a 
genome-wide scale have been reported by multiple groups(108, 143, 190), 
yielding attractive candidates for replication. Unfortunately, the top hits from 
these genome-wide association studies, including EPHA5 and FGD4(143), 
FANCD2(142), and RWDD3(108) are not found on the DMET™ Plus chip and 
could not be assessed in this analysis.  
Our study leveraged the power of the DMET™ Plus chip to simultaneously 
interrogate hundreds of variants that could be relevant to paclitaxel PK. This 
hypothesis-directed discovery approach could be a powerful tool for discovering 
variants in genes not previously recognized to influence drug exposure or 
treatment outcome. However, our results demonstrate one of the fundamental 
limitations of this discovery approach. In the unconditioned analysis, CYP2C8*3, 
which has been reported in multiple independent cohorts to influence paclitaxel-
induced neuropathy, was our 14th highest ranked variant (p=0.016) and did not 
approach our significance threshold (α=0.001). True associations do not 
necessarily show the strongest association in discovery studies(191), and the 
necessity for rigorous statistical correction may lead to many false 
negatives(130).  
In conclusion, we have used a commercially available genotyping panel 
that interrogates variants in genes relevant to drug metabolism, elimination, and 
transport in an attempt to discover and replicate SNPs that modulate risk of 
paclitaxel-induced neurotoxicity through their influence on drug 
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pharmacokinetics. We identified a variant in a gene (ABCG1) that is relevant to 
the regulation of endogenous neuroactive steroids which has not been previously 
investigated in candidate SNP association studies of chemotherapy-induced 
neuropathy to our knowledge. The finding could not be replicated in the smaller 
non-Caucasian cohort, suggesting that the effect may be exclusive to Caucasian 
subjects. Our findings suggest that limited current understanding of biology and 
pharmacology may preclude successful candidate selection and supports the 
continued use of unbiased methods in pharmacogenetic discovery. Ultimately, it 
is essential that the findings from our study, and all discovery studies, are 
successfully replicated in independent populations of patients to validate their 
influence on the phenotype of interest and elucidate their potential for clinical 
utility.    
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TABLES 
Table 3 Characteristics of LCCC 9830 DMET™ Patient Cohort 
  Primary Replication 
Self-reported 
Race 
Caucasian 288 0 
African-American 0 107 (86%) 
Other 0 17 (14%) 
Age (Years)  
Median 52 45 
Range  24-84 22-68 
Grade 2+ 
Neuropathy  
Yes 49 (17%) 28 (23%) 
No 239 (83%) 97 (78%) 
Diabetes 
Diagnosis 
Yes 24 (8%) 24 (19%) 
No 264 (92%) 100 (81%) 
Paclitaxel 
Schedule & 
Dose   
80-90 mg/m2 Weekly 91 (32%) 40 (32%) 
175 mg/m2 Every 2 weeks  163 (57%) 73 (59%) 
175 mg/m2 Every 3 weeks 34 (12%) 11 (9%) 
Supplemental 
Neuropathy 
Therapy 
Glutamine 84 (29%) 28 (23%) 
Gabapentin 7 (2%) 8 (6%) 
Amitriptyline 8 (3%) 1 (1%) 
Vitamin B6 5 (2%) 2 (2%) 
Vitamin B Complex 1 (<1%) 1 (1%) 
None 183 (64%) 85 (69%) 
Cumulative 
Paclitaxel 
(mg/m
2
) 
Median   700 700 
Range 80-1280 80-1280 
Paclitaxel 
Cycles 
Median 4 4 
Range 1-16 1-16 
Treatment Prior 
to Paclitaxel 
AC (Doxorubicin/Cyclophos.) 216 (75%) 100 (81%) 
AC + Bevacizumab 2 (1%) 0 
A (Doxorubicin) 2 (1%) 0 
AC + Docetaxel 0 1 (1%) 
Treatment 
Concurrent to 
Paclitaxel  
Trastuzumab 46 (16%) 25 (20%) 
Bevacizumab 4 (1%) 5 (4%) 
Carboplatin 1 (<1%) 1 (1%) 
Carboplatin + Bevacizumab 1 (<1%) 2 (2%) 
Trastuzumab + Lapatinib 4 (1%) 0 
Trastuzumab + 
Cyclophosphamide 
1 (<1%) 0 
Treatment 
Setting* 
Neoadjuvant 137 (48%) 52 (42%) 
Adjuvant 153 (53%) 73 (59%) 
Counts and percentages (in parentheses) are presented for categorical data. 
Medians and ranges are presented for quantitative data. 
*Three patients were treated with paclitaxel neoadjuvantly and adjuvantly  
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Table 4 DMET™ SNPs Most Strongly Associated with Grade 2+ Neuropathy in 
LCCC 9830 Caucasian Cohort 
Rank Gene Variant rsID CYP2C8*3 
Conditioned 
Fisher’s Exact 
P-Value  
Unconditioned 
Fisher’s Exact 
P-value  
1 ABCG1 (intronic) rs492338 0.0008* 0.0017 
2 CYP4A11 (3’UTR) rs11211402 0.0010 0.0010 
3 CYP4B1_14422C>T(R173W) rs4646487 0.0015 0.0021 
4 GSTA5 (intronic) rs4715354 0.0018 0.0053 
5 ABCG1 (intronic) rs3788007 0.0033 0.0008* 
6 CBR1 (intronic) rs998383 0.0037 0.0074 
7 ABCC1_94714T>C(V275V) rs246221 0.0039 0.0038 
8 GSTA1 (5’ UTR) rs4715332 0.0049 0.0077 
9 SLC16A1_15385T>A(D490E) rs1049434 0.0056 0.0041 
10 CYP17A1_195G>T(S65S) rs6163 0.0066 0.0070 
*Surpassed exploratory α=0.001 
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Table 5 Contingency Table of Grade 2+ Neuropathy Occurrence by Genotype for 
rs492338 
 Genotype Neuropathy 
Incidence 
Odds Ratio Vs. Homozygous Wild-
Type 
ABCG1 
rs492338 
[Intronic]  
C/C 6/66 (9.1%) - 
C/T 23/157 (14.6%) 
OR= 1.70, 95% CI: (0.63- 5.37) 
p=0.38 
T/T 20/62 (32.2%) 
OR= 4.70, 95% CI: (1.64- 15.57) 
p=0.002 
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FIGURE LEGENDS 
 
Figure 7 Incidence curve for grade 2+ neuropathy by ABCG1 (rs492338) 
genotype in Caucasian (n=285) patients.  
 
Figure 8 Incidence curve for grade 2+ neuropathy by ABCG1 (rs492338) 
genotype in non-Caucasian (n=124) patients. 
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FIGURES 
Figure 7 Grade 2+ Neuropathy by rs492338 Genotype for LCCC 9830 
Caucasian Subjects 
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Figure 8 Grade 2+ Neuropathy by rs492338 Genotype for LCCC 9830  
Non-Caucasian Subjects 
Daniel L. Hertz, Kouros Owzar, Hitoshi Zembutsu, Chen Jiang, Jai Patel, Dorothy 
Watson, Mark, L. Ratain, Stefanie D. Krens, Ivo Shterev, Deanna L. Kroetz, 
Susan Halabi, Michiaki Kubo, William Kevin Kelly, Howard L. McLeod. Genome-
wide association study of docetaxel-induced peripheral neuropathy in a hormone 
refractory prostate cancer clinical trial (CALGB 90401) 
 
 
 
CHAPTER IV 
DISCOVER VARIANTS ANYWHERE IN THE GENOME THAT ARE 
ASSOCIATED WITH MODULATED RISK OF EXPERIENCING 
GRADE 3+ NEUROPATHY BY A CUMULATIVE DOSE OF 
DOCETAXEL THROUGH COMPETING-RISKS ANALYSIS AND 
GENOME-WIDE ASSOCIATION 
INTRODUCTION 
The taxane class includes three FDA approved chemotherapeutic agents; 
paclitaxel, docetaxel, and cabazitaxel(14). Taxanes work by binding to and 
stabilizing microtubules, ultimately inhibiting the mitotic phase of cell cycle 
development(50), and are approved for use in breast, gastric, lung, ovarian, and 
prostate cancer. The taxanes and other microtubule targeting chemotherapeutic 
agents such as the vinca alkaloids induce peripheral sensory neuropathy in some 
patients(73). Taxane-induced peripheral neuropathy often presents as a 
combination of paresthesia and dysesthesia, and can progress to irreversible 
loss of function of hands and feet with continued taxane treatment(85).  
The discovery and validation of genetic loci that influence risk of taxane-
induced peripheral neuropathy would be of substantial clinical benefit, enabling 
identification of high risk patients in whom taxane use should be avoided. This is 
particularly critical in tumor types in which the benefit of taxane therapy is 
modest, such as the use of docetaxel in castration-resistant prostate 
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cancer(192). Pharmacogenetic markers that modulate risk of taxane-induced 
neuropathy have been reported from candidate gene studies of both 
paclitaxel(132, 139, 141, 142, 193) and docetaxel(140), and a genome-wide 
analysis of paclitaxel-induced neuropathy has been published(143), however, no 
study has taken a genome-wide approach to discovering genetic loci that 
influence docetaxel-induced neuropathy.  
In this study we performed genome-wide association on a large, 
prospectively enrolled, chemotherapy naive cohort of hormone refractory 
prostate cancer patients who were treated with docetaxel with or without 
bevacizumab for up to 2 years. Because docetaxel therapy was discontinued 
prior to 2 years in many patients we utilized a competing-risks adjusted statistical 
model(194, 195). The primary objective of this study was to discover genetic loci 
that modulate risk of grade 3+ docetaxel-induced peripheral neuropathy in self-
reported, genetically-defined Caucasian patients. Replication was then attempted 
in a genetically-defined Caucasian cohort of paclitaxel treated patients from a 
large prospective clinical trial. 
METHODS 
Patient Cohort 
All patients enrolled on the Cancer and Leukemia Group B (CALGB) 90401 
parent study who provided informed consent for the pharmacogenetic substudy 
(CALGB 60404) were eligible for this pharmacogenetic analysis. For a detailed 
description of the parent study see Kelly et al.(196). Briefly, patient eligibility 
included histologically documented adenocarcinoma of the prostate that had 
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progressed while on hormone deprivation therapy. Relevant exclusion criteria 
included prior chemotherapy or anti-angiogenesis therapy or a documented 
history of grade 2+ neuropathy. Subjects were randomized to receive docetaxel 
based treatment with bevacizumab or placebo for up to two years. Toxicity data 
was collected at each treatment cycle on standardized forms that mandated 
reporting of grade 3+ peripheral sensory neuropathies as defined by NCI CTCAE 
Version 3.0. Only neuropathy that occurred within 30 days of docetaxel treatment 
and was considered possibly, probably, or definitely related to treatment by the 
clinician was included in the analysis.  
Docetaxel Treatment 
All patients received docetaxel 75 mg/m2 infused over 1 hour on day 1 of 
each 21 day cycle with 8 mg oral dexamethasone 12, 3, and 1 hour prior to 
docetaxel infusion. Subjects on both arms also received 5 mg oral prednisone 
twice daily and were randomized to 15 mg/kg bevacizumab or placebo 
intravenous infusion on day 1 of each cycle. Use of growth factor, aspirin, anti-
emetics and luteinizing-hormone releasing hormone agonist were under the 
discretion of the treating physician. Docetaxel administration was held for 
neutropenia (absolute neutrophil count<1,500) or the dose was decreased in 10 
mg/m2 increments for hepatic dysfunction, neurotoxicity, gastrointestinal toxicity, 
or febrile neutropenia. The protocol mandated discontinuation of docetaxel 
treatment if the patient required more than two docetaxel dose decreases or in 
the event of specific severe toxicities or confirmed cancer progression.  
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Genome-Wide Genotyping 
A 10 mL sample of whole blood was collected from all patients enrolling 
on the pharmacogenomic substudy prior to initiation of protocol treatment. 
Genotyping and genetic quality control were similar to that previously reported in 
a CALGB genome-wide association study(143). Genotyping was performed on 
the HumanHap610-Quad Genotyping BeadChip (Illumina, CA, USA) at the 
RIKEN Center for Genomic Medicine (Kanagawa, Japan). Appropriate quality 
control was used to eliminate subjects with call rate <95% and SNPs with call 
rate <99%, poor genotype clustering, or known to be unreliable (Tech Note: 
Infinium® Genotyping Data Analysis, 2007). SNPs with minor allele frequency 
<0.05 or p-value of Hardy-Weinberg distribution >1x10^-08 and all SNPs located 
on the sex chromosomes were also removed, leaving 498,081 SNPs for analysis. 
Eigensoft version 3.0 was used to define genetic ancestry for the 810 subjects 
and only the subjects who were self-reported and genetically-defined as 
Caucasian (n=623) were included in the analysis (Figure 9). 
Statistical Analysis 
The endpoint used in this study was the cumulative dose (mg/m2) at first 
report of grade 3+ sensory peripheral neuropathy. Any patient who did not 
experience neuropathy was censored at their maximum docetaxel dose received. 
The primary statistical analysis utilized a competing-risks adjusted likelihood 
model in which any patient who did not experience neuropathy and did not 
complete the full two years of therapy was classified by their reason for docetaxel 
discontinuation: progression/death, treatment terminating adverse event, or 
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withdrawal/other. Using this data, a likelihood ratio test with 1 degree of freedom 
and 95% confidence intervals was estimated for each SNP assuming an additive 
genetic effect. Any SNP for which the model did not converge was excluded from 
analysis, bringing the final SNP total to 498,022. The top 100 hits were 
subjectively filtered considering the strength of association with neuropathy, 
biological function of the gene, and other publicly available data to create a list of 
priority SNPs for further analysis. The relationship between these SNPs and 
neuropathy was adjusted for clinical covariates with known relevance to 
neuropathy risk: diabetes (reported history of diabetes or current diabetes 
treatment vs. none), age (continuous), body mass index (BMI) (≤ 30 kg/m2 vs. > 
30 kg/m2), and for treatment arm (bevacizumab vs. placebo). We attempted 
replication in an independent cohort of self-reported, genetically-defined 
Caucasians who received paclitaxel for adjuvant breast cancer treatment 
(CALGB 40101)(197). Results of the genome-wide association of the dose-at-
grade 2+ neuropathy occurrence were recently published(143). The p-value of 
association for each SNP on our priority list was compared to a Bonferroni 
corrected p-value threshold.    
RESULTS 
The CALGB 90401 parent study enrolled 1,050 total patients, of whom 
623 self-reported, genetically-defined Caucasian subjects were evaluable in the 
discovery analysis (Figure 10). Relevant demographic characteristics for 
patients, including patient age and relevant covariate data are displayed in Table 
6 for the entire discovery cohort and stratified by whether or not they experienced 
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neuropathy. The overall incidence of grade 3+ sensory neuropathy in the 
discovery population was 8% (50/623). The remaining 573 patients were 
classified as having either completed treatment without neuropathy 
(24/623=3.9%) or categorized based on their reason for docetaxel 
discontinuation: death/progression (38.4%), treatment terminating adverse event 
(31.9%) or withdrawal/other (17.8%) (Table 7). The cumulative distribution of 
neuropathy or competing risk event during docetaxel treatment is displayed in 
Figure 11. As expected, the risk of neuropathy was not significantly different 
based on patient assignment to the bevacizumab or placebo arm (p=0.24) 
(Figure 12). 
The top 100 hits from the discovery analysis including rank, rsID, gene, 
and unadjusted p-value are reported in Table 8. No locus surpassed Bonferroni-
corrected significance (0.05/498,022=1.004x10^-7) though multiple variants 
surpassed a suggestive threshold of 1x10^-6 (Figure 13). The top hit was an 
intergenic SNP (rs11017056, Figure 14) that increased neuropathy risk in a 
seemingly additive manner (HR=2.83, 95%CI: 1.89-4.25, p=5.00x10^-7, Figure 
15). The second ranked hit is an intronic SNP in the VAC14 gene (rs875858) 
which also increased neuropathy risk (HR=3.43, 95%CI: 2.11-5.62, p=7.90x10^-
7, Figure 16).  
Based on the strength of their association these two SNPs were selected 
for inclusion in the final list of priority SNPs (Table 9). This list also includes the 
third ranked SNP (rs10761189) which is found in FGD3, two intronic SNPs 
(rs17185211, p=1.2x10^-5 and rs478472, p=1.80x10^-5) in genes with known 
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relevance to neurodevelopment and neuronal connectivity in the central nervous 
system (DOK6 and NAV1) and two SNPs from the OPCML gene (rs1027796, 
p=4.7x10^-6, rs12805206, p=7.9x10^-5) that were ranked in the top 100 hits and 
are not in strong LD (D’=0.12, r2=0). These 7 SNPs were then adjusted for the 
clinically relevant covariates: diabetes, age, treatment arm, and BMI, and these 
results are also displayed in Table 9. Notably, our top hit rs11017056 surpassed 
the Bonferroni corrected genome-wide significance threshold after covariate 
adjustment (p=7.2x10^-08). 
Each of the 7 priority SNPs was then tested, separately, in the genetically 
defined-Caucasian patients from the CALGB 40101 study at a Bonferroni-
corrected significance threshold of p<0.0071. The results of the attempted 
independent replication are also displayed in Table 9. Though the p-value for our 
top hit (rs11017056, p=0.001) is smaller than the significance threshold, this 
association was not successfully replicated as the direction of effect was 
opposite of that seen in the discovery population (Figure 17). Thus, none of our 
priority SNPs were successfully replicated in the independent cohort of 
paclitaxel-treated patients.    
DISCUSSION 
Chemotherapy-induced peripheral neuropathy is a common, severe 
adverse effect of a variety of chemotherapeutic agents, including the taxanes. 
While docetaxel is somewhat less neurotoxic than paclitaxel(67-70), it does 
necessitate treatment discontinuation in some patients and the ability to identify 
individuals at increased risk of docetaxel-induced neuropathy prior to treatment 
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could be of major clinical benefit. Using a genome-wide pharmacogenetic 
discovery approach we have attempted to identify genetic loci that modulate risk 
of docetaxel-induced peripheral neuropathy in a cohort of 623 Caucasian 
patients. We then attempted to replicate this association in an independent 
population of paclitaxel treated Caucasian patients from the CALGB 40101 study. 
The major strengths of this study are the large, prospectively enrolled, 
chemotherapy naïve patient cohort who received homogeneous docetaxel 
treatment and regular assessment for sensory neuropathy. Our genotyping 
platform and data processing pipeline have been previously used in published 
genome-wide pharmacogenetic analyses that discovered a variant that was 
successfully replicated in two independent populations(143). Another element of 
this study that differentiates it from previous pharmacogenetic analyses is the 
use of the competing-risks adjusted likelihood ratio test. This procedure is 
particularly important in the context of this trial where a large number of patients 
discontinued treatment due to early disease progression, death, or severe 
toxicity, as can be seen in Figure 11. By utilizing the competing-risks approach 
we were able to informatively censor patients who discontinued treatment early 
and test the specific influence of each genetic locus on the endpoint of interest, 
neuropathy occurrence. 
Our top hit (rs11017056), which after covariate adjustment surpassed 
genome-wide significance, is an intergenic SNP located several hundred 
kilobases upstream from the nearest gene, EBF3 (Figure 14). This common 
variant (Minor allele frequency [MAF] =0.22) increased risk of docetaxel-induced 
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neuropathy in this study (HR=2.83). According to the HaploReg database, 
rs11017056 is in complete LD with another intergenic SNP (rs34559138) which 
alters a binding motif for the Forkhead/winged-helix J1 (Foxj1) transcription 
factor(198). This transcription factor coordinates postnatal neurogenesis(199) 
and differentiation of neuronal-associated astrocytes through regulation of a 
network of genes, a large number of which are microtubule-associated 
proteins(200). 
The second ranked hit is a rare (MAF=0.056) intronic SNP within the 
VAC14 (ArPIKfyve) gene that confers increased risk of neuropathy (HR=3.43). 
The VAC14 protein stabilizes FIG4, creating a complex that is responsible for the 
regulation of PI(3,5)P2 and PI5P, which are necessary for neurogeneration(201). 
Interestingly, a rare mutation in the FIG4 gene is known to cause a subtype of 
Charcot-Marie Tooth (CMT) disease, a hereditary neuropathy syndrome(202). 
The previously reported genome-wide pharmacogenetic study of paclitaxel-
induced neuropathy discovered and validated an association for a SNP in FGD4, 
another gene that has been implicated in CMT(143). The third ranked hit is a 
common (MAF=0.389) intronic SNP in the FGD3 gene which had a protective 
effect (HR=0.432). Little is known about FGD3; however, it is of interest based on 
its functional and structural similarity to FGD4 and their involvement in the highly-
conserved cdc42 pathway(203).  
This study discovered several candidates SNPs that were worth following-
up in an independent cohort of taxane-treated patients. Unfortunately, none were 
successfully replicated. There was a statistically significant association between 
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our top hit (rs11017056) and paclitaxel-induced peripheral neuropathy (p=0.001), 
however, the direction of effect was reversed. It is possible that differences 
between the studies, such as the different tumor type or patient gender are the 
cause of our inability to replicate our findings. The most important difference 
between the studies may be the use of paclitaxel instead of docetaxel in CALGB 
40101. It is conceivable that the genetic factors that modulate neuropathy 
sensitivity are different between the taxanes. Though our second highest ranked 
SNP is found in FGD3, we did not detect an association for the FGD4 variant 
previously discovered and replicated in the CALGB 40101 paclitaxel-induced 
neuropathy GWAS (rs10771973, p=0.39), further suggesting that different 
genetic risk factors may exist for the two taxanes.  
One other notable difference between the discovery and replication 
cohorts was the threshold for grade of neuropathy that was considered an event. 
This study did not systematically collect grade 2 peripheral neuropathy, which 
was the endpoint utilized in CALGB 40101. Grade 2 neuropathy is more 
common, improving study power, but grade 3 neuropathy is more clinically 
relevant and patients in this trial were not dose reduced unless they experienced 
grade 3 or higher neurotoxicity. A related limitation is that neuropathy 
assessment is subjective by nature, which may result in inconsistent or 
inaccurate measurement(168). Future prospective studies should seek to 
implement superior neuropathy collection techniques, such as those that rely on 
patient reporting(204).  
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The potential limitations of current neuropathy assessment techniques 
should not deter us from performing genome-wide discovery in the large cohorts 
of patients treated on prospective clinical studies. The SNPs discovered in this 
study may provide key insights into the pathways involved in the development of 
neurotoxicity. Based on our findings it seems that no single variant or gene is 
responsible for dictating patient sensitivity to taxane-induced neuropathy. This is 
consistent with the multifactorial nature of neuropathy which depends on both 
drug exposure and a variety of patient factors(91, 95, 101, 106, 109).  
In conclusion, we have used a prospectively enrolled patient cohort to 
discover SNPs that modulate sensitivity to docetaxel-induced peripheral 
neuropathy. After adjustment we identified a single intergenic SNP (rs11017056) 
that may be acting through abrogation of a Foxj1 regulatory element. The 
association of this SNP could not be replicated in an independent cohort of 
paclitaxel-treated patients. These results suggest that it is unlikely that any single 
variant will be clinically useful for predicting patients’ neuropathy risk when 
treated with docetaxel, however, replication of our results could validate the role 
of these genes or pathways in chemotherapy-induced neuropathy sensitivity.  
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TABLES 
Table 6 Relevant Characteristics of CALGB 90401 Cohort and Patients Stratified 
by Grade 3+ Neuropathy  
 
90401 Cohort  
(n=623) 
Neuropathy Yes  
(n=50) 
Neuropathy No 
(N=573) 
Age  69 (42-94) 73 (55-84) 69 (42-94) 
Diabetes  98 (15.7%) 5 (10.0%) 93 (16.2%) 
Body Mass Index  29.0 (16.1-57.2) 27.0 (16.1-41.7) 29.2 (17.3-53.3) 
Bevacizumab Arm 314 (50.4%) 21 (42.0%) 293 (45.9%) 
Docetaxel Dose 601 (72-2457) 604 (150-1932) 600 (72-2457) 
Medians (and ranges) listed for quantitative data 
Counts (and percentages) listed for categorical data 
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Table 7 CALGB 90401 Patient Classification for Competing-Risks Analysis 
  
 Discovery Cohort 
(n=623) 
Experienced Grade 2+ Neuropathy   50 (9.0%) 
Completed 2 Years of Treatment   24 (3.9%) 
Death or Progression   239 (38.4%) 
 Death  16  
 Progression 223  
Treatment Terminating Adverse Event   199 (31.9%) 
 Neutropenia 20  
 Hypertension 3  
 Thrombosis 10  
 Hemorrhage 29  
 Other 137  
Withdrawal or Other   111 (17.8%) 
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Table 8 100 SNPs with Strongest Association with Grade 3+ Neuropathy in 
90401 Caucasian Subjects 
Rank rsID Chr Position Alleles Gene P-value HR 
1 rs11017056 10 131720630 A/C NA 5.00E-07 2.829 
2 rs875858 16 69332956 C/T VAC14 7.90E-07 3.430 
3 rs10761189 9 94812049 A/G FGD3 3.30E-06 2.313 
4 rs2178728 2 130264445 A/G NA 3.30E-06 2.277 
5 rs8089250 18 4762807 C/T NA 3.60E-06 2.808 
6 rs1566691 5 3780179 C/T NA 4.00E-06 3.437 
7 rs1027796 11 132262880 A/C OPCML 4.70E-06 2.293 
8 rs4076630 9 94721379 C/T NA 5.10E-06 2.282 
9 rs11740657 5 135609558 A/G TRPC7 5.20E-06 2.887 
10 rs13171764 5 3783312 G/T NA 6.40E-06 3.150 
11 rs2792574 14 47746177 A/G NA 6.40E-06 2.274 
12 rs7225402 17 60810368 C/T NA 7.50E-06 3.173 
13 rs4452539 5 75795960 C/T IQGAP2 7.90E-06 0.412 
14 rs17205603 15 60252681 A/C NA 9.30E-06 2.407 
15 rs10992512 9 94692772 A/G NA 1.20E-05 2.213 
16 rs16948569 18 5633771 A/G NA 1.20E-05 2.355 
17 rs17185211 18 65299361 A/G DOK6 1.20E-05 2.295 
18 rs9604512 13 113602860 C/T FAM70B 1.20E-05 3.142 
19 rs6806193 3 181261062 C/T NA 1.30E-05 2.502 
20 rs2117152 3 85487473 A/C NA 1.50E-05 2.162 
21 rs2952605 2 130260216 G/T NA 1.50E-05 2.328 
22 rs3734124 5 135588957 C/T TRPC7 1.60E-05 3.288 
23 rs10501651 11 87205209 A/G NA 1.70E-05 2.729 
24 rs4872356 8 25695246 G/T NA 1.70E-05 1.876 
25 rs7309371 12 31772408 A/G AMN1 1.70E-05 0.420 
26 rs11051552 12 31781869 A/G NA 1.80E-05 0.423 
27 rs4438470 2 228722963 C/T SPHKAP 1.80E-05 2.491 
28 rs478472 1 199892446 A/G NAV1 1.80E-05 3.245 
29 rs9834152 3 181251225 C/T NA 1.80E-05 2.480 
30 rs6489160 12 126325609 C/T NA 1.90E-05 2.431 
31 rs11983040 7 14198205 C/T DGKB 2.00E-05 2.472 
32 rs10997287 10 68088852 C/T CTNNA3 2.10E-05 0.247 
33 rs2068434 5 75815227 C/T IQGAP2 2.20E-05 0.420 
34 rs2079459 7 14195569 C/T DGKB 2.50E-05 2.357 
35 rs13177369 5 61074267 C/T NA 2.60E-05 2.355 
36 rs6873040 5 61079065 C/T NA 2.70E-05 2.394 
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Table 8 (con’t)  
 
Rank rsID Chr Position Alleles Gene P-value HR 
37 rs11720469 3 167963902 A/G NA 3.30E-05 2.118 
38 rs1953136 13 69974544 A/G NA 3.30E-05 2.264 
39 rs10045155 5 75793312 C/T IQGAP2 3.60E-05 2.033 
40 rs7801545 7 42266819 G/T NA 3.60E-05 2.204 
41 rs4889136 16 78928603 A/G LOC729847 3.70E-05 2.490 
42 rs1036837 18 65301877 A/C DOK6 3.90E-05 2.229 
43 rs4382847 10 52236981 G/T A1CF A1CF 4.00E-05 2.309 
44 rs17242471 5 157437693 A/G NA 4.20E-05 2.255 
45 rs4142335 13 69969424 A/C NA 4.20E-05 2.223 
46 rs10484017 14 89262294 C/T NA 4.30E-05 2.523 
47 rs388910 5 125165492 C/T NA 4.50E-05 2.431 
48 rs13392999 2 238167726 G/T RAB17 4.60E-05 2.411 
49 rs4256922 10 52238622 C/T A1CF A1CF 4.60E-05 2.297 
50 rs918462 5 151722764 C/T NA 4.70E-05 0.285 
51 rs943801 6 165912238 C/T PDE10A 4.80E-05 2.132 
52 rs11735066 4 52993145 C/T NA 5.10E-05 3.002 
53 rs1537420 13 102966614 G/T NA 5.10E-05 2.282 
54 rs7306680 12 46406222 A/G NA 5.10E-05 2.129 
55 rs17546000 1 174913623 A/G PAPPA2 5.20E-05 2.478 
56 rs6859984 5 75805324 C/T IQGAP2 5.30E-05 2.045 
57 rs13227391 7 105228545 A/G ATXN7L1 5.40E-05 2.181 
58 rs9649088 7 85221228 A/G NA 5.70E-05 2.277 
59 rs2079460 7 14195474 G/T DGKB 5.90E-05 2.301 
60 rs3008063 6 165923176 A/C PDE10A 5.90E-05 2.120 
61 rs1582329 16 51571503 A/G NA 6.00E-05 2.353 
62 rs6953042 7 85273196 A/G NA 6.10E-05 2.273 
63 rs2394279 10 68095473 C/T CTNNA3 6.40E-05 0.418 
64 rs10511298 3 112750254 C/T CD96 6.60E-05 1.935 
65 rs9529745 13 69922412 C/T NA 6.70E-05 2.192 
66 rs4332809 18 35983775 A/C NA 6.90E-05 2.216 
67 rs2339624 10 52355203 A/G NA 7.00E-05 3.220 
68 rs10229660 7 42270739 G/T NA 7.20E-05 2.304 
69 rs2827145 21 22237762 C/T NA 7.20E-05 2.060 
70 rs7242363 18 36002902 A/G NA 7.20E-05 2.213 
71 rs6003807 22 22264030 G/T NA 7.30E-05 2.701 
72 rs6769847 3 145018234 A/G SLC9A9 7.50E-05 3.487 
73 rs11051544 12 31758100 G/T AMN1 7.70E-05 2.231 
74 rs7428372 3 167966753 A/C NA 7.70E-05 2.058 
75 rs12805206 11 132295116 C/T OPCML 7.90E-05 2.329 
76 rs11658557 17 39849711 A/G GPATCH8 8.00E-05 2.787 
77 rs1646691 7 133690170 A/C NA 8.00E-05 2.087 
78 rs11216048 11 116000269 A/G NA 8.20E-05 2.437 
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Table 8 (con’t)  
 
Rank rsID Chr Position Alleles Gene P-value HR 
79 rs4307756 0 NA NA NA 8.20E-05 2.437 
80 rs9677476 2 231834534 A/G ARMC9 8.20E-05 2.105 
81 rs3008542 1 112322163 A/G KCND3 8.50E-05 2.530 
82 rs11223273 11 132280051 C/T OPCML 8.60E-05 2.216 
83 rs6504303 17 60823669 C/T NA 8.60E-05 2.926 
84 rs914906 13 69927917 A/G NA 8.60E-05 2.154 
85 rs1930887 13 69959984 C/T NA 8.70E-05 2.343 
86 rs1524037 2 195899339 A/G NA 9.30E-05 2.427 
87 rs16839537 2 195903999 A/C NA 9.30E-05 2.427 
88 rs377239 21 36860599 C/T NA 9.90E-05 0.392 
89 rs1086520 1 174951426 A/G PAPPA2 1.00E-04 2.305 
90 rs11612613 12 102784338 C/T NA 1.00E-04 2.088 
91 rs12904522 15 31337548 A/G NA 1.00E-04 0.424 
92 rs17151283 5 123538098 C/T NA 1.00E-04 2.790 
93 rs2339024 5 141585436 A/G NA 1.00E-04 2.476 
94 rs961909 18 65261636 A/G DOK6 1.00E-04 2.135 
95 rs11723493 4 37241658 C/T C4orf19 0.00011 2.138 
96 rs1776947 20 4874855 A/G SLC23A2 0.00011 2.896 
97 rs2196096 3 85553332 C/T NA 0.00011 2.153 
98 rs2700007 13 100832284 G/T NALCN 0.00011 2.879 
99 rs3816024 5 108463913 C/T FER 0.00011 2.287 
100 rs7505612 18 4766396 A/C NA 0.00011 2.481 
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Table 9 List of priority SNPs from GWAS Discovery in CALGB 90401 
Rank rsID Gene MAF HR (95% CI) 
Unadj.  
p-value 
Adj.  
p-value 
Replication 
p-value 
1 rs11017056 - 0.22 2.83 (1.89-4.25) 5.0E-07 7.2E-08* 0.001** 
2 rs875858 VAC14 0.06 3.43 (2.11-5.62) 7.9E-07 1.6E-06 0.702 
3 rs10761189 FGD3 0.40 2.32 (1.63-3.30) 3.3E-06 5.3E-06 0.987 
7 rs1027796 OPCML 0.30 2.29(1.61-3.28) 4.7E-06 8.3E-06 0.305 
17 rs17185211 DOK6 0.23 2.30 (1.58-3.33) 1.2E-05 3.4E-05 0.274 
28 rs478472 NAV1 0.08 3.25 (1.90-5.56) 1.8E-05 2.2E-05 0.234 
75 rs12805206 OPCML 0.22 2.33 (1.53-3.55) 7.9E-05 1.3E-04 0.053 
*: Surpassed Bonferroni-corrected genome-wide significance threshold 
**: Direction of effect was opposite of that seen in discovery cohort  
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FIGURE LEGENDS  
Figure 9 Principal Components Analysis was used to define the genetically 
European subcohort for discovery. Any individual who fell more than 2 standard 
deviations from the median for any of the first three eigenvectors was excluded 
from the analysis leaving 623 subjects.   
 
Figure 10 CONSORT Diagram specifying patient flow from enrollment on parent 
study to patients included in genome-wide discovery analysis. 
 
Figure 11 Cumulative incidence of grade 3+ neuropathy and competing risks. 
The early rise in the death/progression and time to adverse event (TTAE) lines 
reflects the large number of patients discontinuing docetaxel treatment early in 
therapy.   
 
Figure 12 Cumulative incidence of grade 3+ neuropathy stratified by treatment 
arm for the 90401 cohort demonstrating no influence of bevacizumab on 
neuropathy risk. 
 
Figure 13 Manhattan plot for unadjusted association with grade 3+ neuropathy in 
Caucasian patients (n=623) for all SNPs that passed the QC filter (n=498,022). 
While no SNPs were significant at the genome-wide threshold (1x10^-8), two 
SNPs (rs11017056 and rs875858) surpassed a suggestive threshold of 1x10^-6. 
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Figure 14 SNAP plot of our top hit (rs11017056) displaying that it is an intergenic 
SNP that is approximately 100kb from the nearest gene (EBF3) and not in LD 
with any SNPs that are within any gene. 
 
Figure 15 Cumulative incidence of grade 3+ neuropathy in CALGB 90401 
genetic Europeans stratified by genotype for the top hit (rs11017056).  
 
Figure 16 Cumulative incidence of grade 3+ neuropathy by genotype for the 
second ranked hit (rs875858) in the 90401 discovery cohort demonstrating an 
increased risk in heterozygous as compared to wild-type patients. Only three 
patients were homozygous for the variant allele, none of whom experienced 
neuropathy. 
 
Figure 17 Attempted replication of the association between our top hit 
(rs11017056) and incidence of neuropathy (grade 2+) in CALGB 40101 genetic 
Europeans showing a significant association in the reverse direction.  
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FIGURES 
Figure 9 Principal Components Analysis of CALGB 90401 Cohort
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Figure 10 Consort Diagram for Patients Included in CALGB 90401 Neuropathy 
GWAS 
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Figure 11 Cumulative Incidence of Grade 3+ Neuropathy and Competing Risks 
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Figure 12 Cumulative Incidence of Grade 3+ Neuropathy Stratified by Treatment 
Arm 
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Figure 13 Manhattan Plot of Results for All SNPs Included in CALGB 90401 
GWAS 
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Figure 14 SNAP Plot of rs11017056 
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Figure 15 Incidence of Grade 3+ Neuropathy Stratified by rs11017056 Genotype 
in CALGB 90401 
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Figure 16 Incidence of Grade 3+ Neuropathy Stratified by rs875858 Genotype in 
CALGB 90401 
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Figure 17 Incidence of Grade 2+ Neuropathy by rs11017056 Genotype in 
CALGB 40101 
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CHAPTER V 
DISCUSSION AND PERSPECTIVE 
 
The taxanes are commonly used in a variety of solid tumor types including 
breast, prostate, lung, and ovarian cancer. They are a highly effective class of 
chemotherapeutic agents, prolonging progression free and overall survival when 
added to the standard of care in different treatment settings. Along with this 
impressive efficacy, though, taxanes are associated with a spectrum of adverse 
effects. One of the most common severe toxicities seen with taxane treatment is 
sensory peripheral neuropathy. Peripheral neuropathy manifests in the hands 
and feet and can cause irreversible loss of balance and inability to perform tasks 
that require fine motor skills and dexterity. Thus, neurotoxicity appearance 
requires discontinuation of taxane treatment to prevent permanent damage, 
limiting the overall effectiveness of taxane therapy. 
In head-to-head studies paclitaxel is somewhat more neurotoxic than 
docetaxel but it is unclear what mechanism is responsible for the disparity 
between the closely related agents. There are neither accurate methods to 
predict which patients are at elevated risk nor effective agents for neuropathy 
prevention or treatment. Because we lack remedies for neuropathy the ability to 
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identify patient factors that predispose an individual to neuropathy development 
would be of substantial clinical benefit. These patients could be monitored more 
closely or offered alternative treatment regimens. Prior work has suggests that 
increased cumulative drug exposure is one factor that determines neuropathy 
risk. In addition, some patients are more sensitive to neuropathy development at 
equivalent exposure, suggesting that there are other unknown factors that 
modulate a patient’s risk of TIPN.  
Some predictors of both drug exposure and patient sensitivity have been 
identified. Drug exposure is determined by the interplay of various factors, 
including the activity of enzymes and transporters involved in taxane distribution 
and elimination. Somewhat less is known about the factors that influence a 
patient’s sensitivity to neuropathy, though advanced age, prior neuropathy, and 
non-Caucasian race have all been suggested to increase risk. In some cases it is 
unclear whether each factor is acting through a modulation of patient sensitivity 
or drug exposure or a combination of the two.  
One likely source of inter-patient variability in drug exposure and patient 
sensitivity is germline genetic variation. Germline variation could influence 
neuropathy risk in a variety of ways including modulated expression or activity of 
enzymes or transporters or inability to properly respond to neurotoxicity 
secondary to variation in cellular signaling pathways. Thus, in order to 
comprehensively study the genetic predictors of neuropathy risk it is essential to 
utilize a variety of approaches, interrogating both candidate variants and the 
entire genome. The central aim of this dissertation was to discover and validate 
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pharmacogenetic predictors of taxane-induced peripheral neuropathy using a 
variety of genotyping and analysis techniques.  
Chapter 2 was an attempt to validate an earlier finding that patients who 
carry the CYP2C8*3 variant are at increased risk of paclitaxel induced 
neuropathy. Because paclitaxel is mainly eliminated through metabolic 
conversion by CYP2C8, this somewhat common, diminished-activity variant was 
a high priority candidate and has demonstrated an increase in neuropathy risk in 
multiple independent patient cohorts. Chapter 3 was an attempt to discover 
variants that modulate the risk of paclitaxel-induced neuropathy after accounting 
for the influence of CYP2C8*3. Based on the known relationship between drug 
exposure and neuropathy risk, a genotyping platform that interrogates much of 
the known variability relevant to Drug Metabolism, Elimination, and Transport 
(DMET™) was utilized in a hypothesis-driven discovery study. In Chapter 4 the 
entire genome was interrogated in an unbiased manner to discover genetic loci 
that modulate a patient’s risk of docetaxel-induced neuropathy. The goal of this 
concluding chapter is to put the results of these three chapters into context and 
suggest future areas for investigation.   
 CHAPTER 2 
An association between CYP2C8*3 and increased risk of neuropathy had 
been previously reported in two paclitaxel studies that investigated multiple 
variants and phenotypes(131, 132). Within a secondary analysis of a 
pharmacogenetic study in breast cancer patients treated neoadjuvantly with 
paclitaxel I identified a trend in the same direction(133)(Appendix 1). This was 
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the prior data on which I based my hypothesis that a larger, racially stratified 
cohort of paclitaxel treated patients could be used to validate the association 
between CYP2C8*3 and increased risk of peripheral neuropathy. 
Because the CYP2C8*3 variant is more common in European-American 
(CEU AF=0.14) than African-American (ASW AF=0.04) individuals, the study 
cohort was stratified by self-reported race. In the primary analysis of Caucasian 
individuals who had not been previously analyzed, the association between 
CYP2C8*3 and increased risk of neuropathy was validated (HR (per allele) = 
1.93 (95% CI: 1.05- 3.55), overall log-rank p=0.006). The association was also 
replicated in the African-American patients (p=0.043), despite the low allele 
frequency and absence of any variant homozygous individuals. Having two 
positive independent replications, all of the paclitaxel treated patients were 
combined into a single multivariable model that included clinical characteristics 
that are likely to be relevant to neuropathy development (age, race, diabetes, 
treatment schedule, neuropathy treatment). After backward elimination the final 
model demonstrated an additive genetic effect; each CYP2C8*3 variant carried 
by a patient approximately doubled their risk of neuropathy (p=0.031). In addition, 
patients who are non-Caucasian were at higher risk of neuropathy as compared 
to Caucasians of a similar genotype (HR=1.76, 95%CI: 1.05-2.93, p=0.031) a 
finding that had been recently published by another group(109).  
Many candidate gene studies interrogate multiple genotypes and 
phenotypes and carry out dozens of statistical associations without proper 
statistical correction, leading to a slew of false positives(130). Clinical validation 
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of an association requires replication in an independent patient cohort with an a 
priori defined analysis plan and rigorous statistical methodology. The successful 
replication of the CYP2C8*3 association in this large patient cohort that analyzed 
a single genotype-phenotype association is compelling evidence of clinical 
validity. The next logical step is the translation of this finding to clinical practice. 
Clinical translation of this finding could proceed in a variety of directions. 
One potential area for further research is to look more closely at the other 
variants within CYP2C8, specifically the *2 (rs11572103, I269F, YRI AF=0.20), *4 
(rs1058930, I264M, CEU AF=0.07) and Haplotype C variants (rs1113129, CEU 
AF=0.19, YRI AF=0.50), all three of which have shown decreased metabolic 
activity(205-207). The genotyping platform that I utilized interrogated the *2 and 
*4 alleles and in a secondary analysis the association of these variants with 
increased neuropathy risk was investigated. First, any patient who carried a risk 
allele was collapsed into a ‘low-metabolizers’ group and compared with all other 
patients. The results of this analyses were statistically significant (HR=1.722, 
95% CI 1.10-2.70, p=0.018) (Figure 18). Next, a likelihood ratio test was used to 
determine whether this association was driven entirely by the *3 variant. 
Removing the *3 variant significantly diminished the performance of the test 
(p=0.037) while removing either of the other SNPs did not (*2 p=0.172, *4 
p=0.214) demonstrating that neither SNP individually contributed significant 
explanatory information to the overall model and the association in the low-
metabolizer group was being driven primarily by the *3 variant. Unfortunately, the 
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DMET™ Plus chip does not interrogate the Haplotype C SNP, which has 
previously been reported to influence neuropathy risk(132).  
Another potential area for follow-up work is the use of modeling and 
simulation to assist in clinical translation. Using the data from this study it is 
possible to model the cumulative paclitaxel dose at which patients of each 
genotype would have equivalent toxicity risk, as has been done previously for 
other SNPs(143). A similar approach would be to use data from 
pharmacogenetic-pharmacokinetic modeling to simulate the dose that would 
normalize drug exposure across patients of different genotypes. Based on data 
from Bergmann et al. the clearance of free paclitaxel is approximately 10% lower 
for CYP2C8*3 heterozygotes as compared to wild-type homozygotes(155). Our 
results suggest that the effect of the *3 variant mimics an additive genetic model, 
implying that the decrease in paclitaxel clearance may also be linearly related to 
the number of variant alleles a patient carries. Interestingly, based on our data 
the risk of neuropathy is less than 20% in the wild-type patients suggesting that 
their optimal dose is higher than the doses currently used clinically. According to 
our neoadjuvant study (Appendix 1) this under-dosing is causing suboptimal 
treatment efficacy. Thus, one could envision a scenario where pre-treatment 
genotyping could lead to increased paclitaxel dosing in the 74% of Caucasian 
patients who are CYP2C8 wild-type homozygotes, improving the efficacy of their 
treatment at an acceptable toxicity risk. One should be cautioned though that 
empirical treatment with 100 mg/m2 weekly, a 25% increase over the standard 80 
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mg/m2 regimen, has been reported to have unacceptable rates of peripheral 
neuropathy development(97). 
A slightly more ambitious project would be to incorporate CYP2C8 
genotype data into models that utilize individual patient data, such as weight, 
age, bilirubin level, and gender, to estimate the dose-exposure relationship. 
Integrating clinical and genetic factors is an attractive approach to select 
individualized starting doses for patients who are initiating taxane therapy, and 
would likely attenuate some of the inter-individual variability in drug exposure 
seen in the initial cycles of treatment(208).     
The association between CYP2C8*3 and peripheral neuropathy was 
consistent in direction and magnitude in the non-Caucasian subgroup, supporting 
the hypothesis that the *3 variant is causative. The low frequency of the variant in 
non-Caucasians decreases the cost-benefit ratio of pre-treatment 
pharmacogenetic testing but patients who are known to be *3 carriers, regardless 
of race, should be considered to be at higher neuropathy risk. More interestingly, 
this study replicated a previously reported finding that non-Caucasians are at 
higher neuropathy risk than Caucasians of similar genotype, even after 
attempted adjustment for diabetes and other risk factors. This suggests that there 
are other factors at play in the etiology of neuropathy, potentially other genetic 
factors that are yet to be discovered. The small number of non-Caucasians 
enrolled in clinical trials, and particularly in pharmacogenetic studies, presents a 
challenge to the discovery of these loci, however, this limitation may be 
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surmountable within a planned meta-analysis of three large paclitaxel-induced 
neuropathy genome-wide association studies.    
CHAPTER 3 
The aim of this chapter was to discover and validate SNPs in genes 
relevant to paclitaxel pharmacokinetics that influence neuropathy risk. In order to 
do so, genotyping was carried out on the Affymetrix DMET™ Plus chip, which 
interrogates 1,936 variants in genes responsible for drug metabolism, 
elimination, and transport. This chip directly assays high priority variants in 
hundreds of genes, including those that code for the transporters (P-gp, MRP2, 
SLCO1B3) and enzymes (CYP2C8, CYP3A4) known to be involved in paclitaxel 
distribution and elimination. I hypothesized that taking a comprehensive 
approach to interrogating these variants would enable me to validate findings 
from previous candidate-gene studies and/or discover novel variants that 
influence the risk of paclitaxel-induced neuropathy through modulation of drug 
pharmacokinetics. Because of the previously demonstrated influence of 
CYP2C8*3 on the risk of neuropathy (Chapter 2) the analysis was conditioned on 
this variant, enabling discovery of loci that explain the residual variability in 
neuropathy development.  
Surprisingly, this study identified a SNP (rs492388) found within a gene 
that is not relevant to paclitaxel pharmacokinetics. The SNP that surpassed the 
exploratory significance threshold (p=0.0008) is located in an intronic region of 
the ABCG1 gene. ABCG1 is an intracellular transporter that regulates cholesterol 
homeostasis, particularly in macrophages, but also in peripheral neurons. Within 
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neurons, cholesterol is metabolized to pregnenolone and progesterone, two 
molecules that can be converted to androgen and estrogens. Alternatively, 
pregnenolone and progesterone can be metabolized to “neuroactive steroids,” 
which are key regulators of Schwann cell function and myelin formation(186, 
187). These neuroactive steroids are integral to the neurodegenerative response, 
providing a plausible mechanism through which these variants could modulate 
risk of paclitaxel-induced neuropathy.  
The relationship between rs492388, or another SNP in high LD with this 
marker, and paclitaxel-induced neuropathy risk requires replication in an 
independent patient cohort, similar to that accomplished in Chapter 2 for 
CYP2C8*3. The association of the ABCG1 SNP and peripheral neuropathy could 
not be replicated in 124 self-reported non-Caucasian patients from the 9830 
cohort (p=0.542). There are several potential reasons that replication in a 
different racial cohort could be problematic. One possible reason would be 
differences in minor allele frequency, specifically, low allele frequency in the 
replication cohort. This does not seem to be the case for rs492388 which has 
sufficient genetic variability in the 9830 non-Caucasians (MAF=0.40). It is also 
possible that the association in the Caucasian patients is not directly due to this 
intronic variant, but is instead caused by another SNP in high LD with rs492388, 
and that this effect is abrogated in non-Caucasians due to differences in 
haplotype structure. Using the publicly available FastSNP database the SNPs in 
LD with our hit were interrogated to search for a likely causative variant, 
however, no obvious candidates could be identified(209). As discussed earlier, 
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the pharmacogenetics literature is full of false-positive associations that could not 
be replicated in additional patient cohort(210) and it may be the case that the 
relationship between rs492388 and paclitaxel-induced neuropathy is merely a 
spurious association.  
One important distinction between the statistical analyses employed in 
Chapters 2 and 3 is the use of dose-to-neuropathy (Chapter 2) versus 
neuropathy occurrence (Chapter 3). Because cumulative dose is a known risk 
factor for neuropathy development, a dose-to-neuropathy analysis is a superior 
statistical methodology. This is apparent in the results from Chapter 2 in which 
the log-rank test (p=0.006) was more sensitive than the Fisher’s test (p=0.042). 
In Chapter 3 the cumulative dose at neuropathy occurrence could not be used as 
it was extremely sensitive to neuropathies early in therapy in patients carrying 
rare SNPs. One SNP in particular (rs7770619) had highly significant results using 
a log-rank test (p=1.25x10^-9) that were driven almost entirely by a single 
homozygous variant subject who experienced neuropathy early in treatment 
(Figure 19). Reanalysis after exclusion of this one subject yielded a p-value that 
is consistent with the null hypothesis (p=0.27). Therefore, caution should be used 
in interpreting results from dose-to-event analyses when small numbers of 
patients represent entire genotype groups.  
This study was unable to validate the influence of any SNP or gene 
relevant to paclitaxel pharmacokinetics on neuropathy risk. This could be 
because no other SNPs have an appreciable influence on PK, or it could be a 
lack of sensitivity of our phenotype (neuropathy) as a surrogate of PK. A more 
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sensitive approach for follow-up investigation would be to collect rich 
pharmacokinetic data and directly investigate the influence of genetic and clinical 
factors on PK variability. Work in this area is currently underway by groups 
utilizing population and physiologically based pharmacokinetic models(40, 45, 
170). Some interesting hypotheses have been proposed based on these tools; 
for instance, it was recently reported that metabolite levels may be highly 
sensitive to changes in transport and metabolism(211). It has long been thought 
that the metabolites of paclitaxel are inactive and unrelated to treatment efficacy 
and toxicity(30) but it may be that some patients experience supertherapeutic 
exposure to a paclitaxel metabolite that is neurotoxic. This could explain the 
unexpected increase in neuropathy risk for paclitaxel treated patients who carry 
high-activity CYP3A4/5 variants(132). Perhaps it would be worthwhile revisiting 
what we think we know about the pharmacology of paclitaxel and its metabolites 
using established rodent chemotherapy-induced neuropathy models. 
CHAPTER 4 
No previous study had utilized a genome-wide approach to discover loci 
that modulate docetaxel-induced peripheral neuropathy, which was the goal of 
Chapter 4. I then attempted to use a previously reported paclitaxel-induced 
neuropathy GWAS for replication.  
Most PGx studies use a simple case-control approach, where patients 
who did not experience the event of interest (controls) are compared with 
patients who did experience the event (cases), as was performed in Chapter 3. 
For endpoints that are related to time (such as survival) or cumulative treatment 
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(such as neuropathy) a log-rank analysis with the time or dose-at-event is 
utilized(132, 143), as was performed in Chapter 2. In the log-rank procedure any 
patient who did not experience neuropathy is uninformatively censored at their 
cumulative dose received and classified as a control for analysis(212). 
Patients with hormone refractory prostate cancer who are being initiated 
on docetaxel treatment, such as those patients enrolled on CALGB 90401, have 
very poor prognosis and many progress or die early in therapy. Using the 
standard log-rank procedure these patients would be classified as ‘controls’ 
despite discontinuation of treatment at cumulative docetaxel doses below those 
at which neuropathy typically develops. This censoring would lead to inflation in 
the estimate of neuropathy risk(213). Instead, we utilized the competing-risks 
technique which censors patients in an informative manner(194). Any patient 
who discontinued treatment prior to neuropathy was categorized by their reason 
for discontinuation, enabling us to accurately estimate the risk of neuropathy 
during docetaxel treatment and use this superior phenotype for genome-wide 
discovery.  
Using the competing-risk model we identified several promising candidate 
SNPs for docetaxel-induced peripheral neuropathy. The variant with the 
strongest association with neuropathy (rs11017056) was an intergenic SNP that 
surpassed genome-wide significance after adjustment for relevant clinical 
covariates (p=7.2x10^-8). GWAS studies have discovered and validated many 
intergenic SNPs that have phenotypic consequences. Our current understanding 
of intergenic regions is extraordinarily limited. Using publicly available data I 
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determined that our intergenic SNP is in high LD with a SNP that modifies a 
binding site for the Foxj1 transcription factor, which is necessary for 
neurogenesis and neurodevelopment. Additional research that leads to improved 
understanding of the mechanisms by which variation in intergenic regions 
influences biology, such as the work done within the encode project(114), is of 
paramount importance in the interpretation of GWAS findings. 
The SNPs with the 2nd and 3rd strongest association with docetaxel-
induced neuropathy are both located within genes that are indirectly related to 
Charcot-Marie-Tooth disease. The first SNP is found in VAC14 which forms a 
complex with FIG4, the gene responsible for CMT type4J(202). The other SNP is 
found in the gene encoding FGD3, a paralog of the FGD4 protein which is 
causative of CMT type4H(214). In retrospect it makes sense that we would 
discover SNPs located within genes relevant to a familial neuropathy condition, 
however, the complexity of human biology and our naïve understanding of 
pharmacology precludes successful a priori selection of genes and variants for 
association testing. These findings support continued use of genome-wide 
discovery methods, in parallel with candidate-gene validation, in PGx research. 
They also highlight the need for continued basic science research to characterize 
the biological functions of all human genes and the further elucidation of gene 
pathways(175) to enable understanding of the mechanism by which different 
gene variants are having similar biological consequences. This too will assist with 
the interpretation of genome-wide discovery studies that seek to understand 
genetic drivers of drug response.  
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I then attempted to replicate these priority SNPs in the paclitaxel-treated 
patients from the CALGB 40101 study, with the assumption that the genetic 
factors of neuropathy risk would be similar between the two taxanes. 
Interestingly, the top hit from the discovery study showed an association in the 
reverse direction in the replication cohort (p=0.010). This is most likely evidence 
that the original finding was a spurious association, but there remains a 
possibility that genetic variants that influence docetaxel- and paclitaxel-induced 
peripheral neuropathy are distinct. This hypothesis is supported by the lack of 
association in our study for the variant discovered and replicated in the CALGB 
40101 PGx analysis (rs10771973, p=0.39).  
None of our priority SNPs were successfully replicated in the paclitaxel-
treated cohort. Until replication is attempted in additional cohorts of docetaxel 
treated patients it is not possible to truly determine whether these original 
findings were spurious or these loci are specific to docetaxel-induced 
neuropathy. Because peripheral neuropathy is not the dose-limiting toxicity of 
docetaxel, little work has been done on elucidating the clinical and genetic risk 
factors of docetaxel-induced peripheral neuropathy. Large populations of 
docetaxel-treated patients will need to be retrospectively analyzed to determine 
what degree of overlap exists between these risk factors.  
Successful replication of the loci discovered in CALGB 90401, or those 
discovered in other docetaxel-induced neuropathy GWAS, should motivate 
additional research into the translation of these findings. Forward translation, into 
clinical practice, would entail pretreatment genotyping to identify patients at 
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increased risk of neuropathy who are candidates for modified dosing or 
alternative treatment regimens. However, based on the findings of this study it is 
unlikely that any single SNP is influential enough to be used clinically for this 
purpose. It is more likely that validated loci will be useful in exploring the 
pharmacology of docetaxel and the biological mechanisms underlying TIPN. 
Improved understanding of neurotoxicity etiology may help identify attractive drug 
targets to guide the design of therapeutics that effectively prevent or reverse 
taxane-induced neuropathy development.   
CONCLUDING REMARKS 
The overall goal of this dissertation was to discover and validate germline 
genetic loci that modulate risk of taxane-induced neuropathy. This was 
accomplished in a variety of patient cohorts using different analysis and 
genotyping techniques selected based on the particular hypothesis and situation. 
I first replicated in multiple independent patient cohorts an increase in neuropathy 
risk for the low-activity CYP2C8*3 variant. Clinical translation of this association, 
possibly through characterizing the relationships between CYP2C8 genotype, 
paclitaxel exposure and neuropathy development, could ultimately enable 
clinicians to individualize paclitaxel treatment to optimize therapeutic outcomes. I 
then used a genotyping panel that interrogates variants in genes relevant to drug 
pharmacokinetics to explain the residual variability in neuropathy risk in this 
patient cohort. The intent was to discover or validate other SNPs which, through 
a modulation of paclitaxel pharmacokinetics, influence neuropathy risk. The SNP 
that I found instead is located in a gene (ABCG1) relevant to the regulation of 
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neuroactive steroids. Finally, I used a genome-wide discovery approach in a 
cohort of docetaxel treated patients, leading to the discovery of a single 
intergenic SNP that may increase neuropathy risk in docetaxel-treated patients. 
Successful replication of the influence of either of these SNPs on taxane-induced 
neuropathy could enable pretreatment identification of patients at high risk of 
neuropathy, expand our understanding of the underlying mechanism of TIPN, 
and/or suggest novel targets for therapeutic strategies that prevent or treat 
neuropathy. Any of these outcomes would major breakthroughs in cancer 
treatment.  
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FIGURE LEGENDS  
 
Figure 18 Incidence of grade 2+ neuropathy by metabolizer status collapsing all 
patients carrying a CYP2C8*2, *3 or *4 allele into a low-metabolizer phenotype 
for the 9830 cohort (n=412).  
 
Figure 19 Incidence curve of dose-to-grade 2+ neuropathy for rs7770619 
(PPARD, p=1.25x10^-9). Without the single homozygous variant subject the p-
value of association is 0.27, demonstrating the sensitivity of this analysis method. 
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FIGURES 
Figure 18 Incidence of Grade 2+ Neuropathy by Metabolizer Status in LCCC 
9830 
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Figure 19 Incidence of Dose-at-Grade 2+ Neuropathy for rs7770619 
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APPENDIX 1 
CYP2C8*3 PREDICTS BENEFIT/RISK PROFILE IN BREAST 
CANCER PATIENTS RECEIVING NEOADJUVANT PACLITAXEL  
INTRODUCTION 
Interpatient variability in toxicity and response are important problems in 
the use of cancer chemotherapy. For example, paclitaxel, one of the most 
commonly used therapies for breast cancer and other cancers, has interpatient 
variability of 19-26% in (unbound) drug clearance(45), causes grade 3 or higher 
neuropathy and neutropenia in 5-8% and 2-4% of patients, respectively(148) and 
a response rate as first line, single agent treatment in metastatic breast cancer of 
20-30%(215). Studying host factors responsible for the variability in 
chemotherapeutic outcomes and developing strategies to individualize therapy in 
order to maximize response and minimize toxicity is an active area of research. 
Pharmacogenomics, study of the interplay of genetics and drug therapy 
outcomes, is one promising approach to achieving individualized therapy(110). 
Genetic variation can influence therapy by a number of mechanisms. Variants in 
genes relevant to drug disposition or metabolism can modulate the patient’s 
exposure to the drug, whereas variation in genes that are involved in drug action 
can influence the patient’s sensitivity. For example, germline genetic 
polymorphisms have been discovered which increase the likelihood of a patient 
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experiencing severe toxicity to irinotecan(216, 217) or modulate the optimal dose 
of a patient’s warfarin therapy(122).  
 A number of putative pharmacogenetic markers for paclitaxel outcomes, in 
breast cancer and in other solid tumors, have been evaluated(108, 132, 135, 
139, 143, 172-174, 190, 218, 219). Most of these studies focused on known 
mutations in biologically relevant candidate genes such as CYP2C8, CYP3A4, 
and ABCB1, which code for the enzymes involved in paclitaxel metabolism and 
the transporters that influence paclitaxel disposition. More recent genome-wide 
association studies used an unbiased approach to examine the entire genome to 
address this question, and have reported intriguing candidate SNPs in genes not 
previously investigated(108, 143, 190). The clinical phenotypes most often 
studied were severe toxicities, such as neuropathy, or measures of survival. 
Some of these retrospective pharmacogenetic studies suggest that genetic 
variability may be associated with clinical outcome to paclitaxel therapy, and 
others do not. However, the toxicity endpoints are often confounded by prior or 
combination therapy, while the survival endpoint is confounded by a multitude of 
factors including ER status or tumor subtype(220) and stage at diagnosis(221). 
To our knowledge, no published pharmacogenomic study has exclusively utilized 
a neoadjuvantly treated population, in which toxicity and tumor response to 
paclitaxel therapy can be assessed in the absence of these confounding factors.  
In the current study, we genotyped a cohort of patients treated with 
neoadjuvant paclitaxel for polymorphisms that have previously demonstrated 
significant associations with efficacy or toxicity. These subjects are uniquely 
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informative since tumor response and toxicity data were collected exclusively for 
the taxane treatment phase. We hypothesized that polymorphisms in genes 
relevant to paclitaxel metabolism (CYP2C8 & CYP3A4/3A5), transport (ABCB1), 
or mechanism (CYP1B1) would influence the likelihood that a patient would 
respond to, or experience severe toxicity from, paclitaxel therapy.  
MATERIALS AND METHODS 
Patients and Treatments  
Relevant candidate SNPs were evaluated in a cohort of patients treated 
between 2005 and 2009 and derived from the University of North Carolina 
Lineberger Comprehensive Cancer Center (UNC LCCC) Breast Cancer 
Neoadjuvant Database, which includes prospective annotation of clinical data, 
treatment details, toxicity and outcome. Eligible women received neoadjuvant 
paclitaxel-containing regimens and enrolled in both the UNC neoadjuvant 
database and a concurrent IRB approved clinical trial that collected genomic 
DNA from all newly diagnosed patients. All patients received paclitaxel (T) 
treatment guided by standard neoadjuvant protocols which had a defined and 
conventional treatment dose, schedule, and duration. In most cases patients 
received neoadjuvant doxorubicin and cyclophosphamide (AC) either before or 
after the paclitaxel; however, the tumors were measured before and after each 
phase of therapy so that clinical response to the anthracycline component and 
the taxane component could be identified separately. Some patients with HER2 
over-expressing tumors received trastuzumab concurrent with the paclitaxel. 
Tumor size was measured clinically by the patient’s medical oncologist and 
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percent change in tumor size was calculated from these measurements. Clinical 
response was defined as: complete response (cCR; 100% reduction in tumor 
size), partial response (cPR; 30%-99% reduction), stable disease (cSD; 29% 
reduction-20% enlargement of tumor) or progressive disease (cPD; >20% 
enlargement) according to RECIST criteria (222). Patients who achieved 
complete response to AC before the start of taxane therapy were excluded from 
the efficacy analysis because they were not evaluable for response to taxane 
treatment. Pathological response, which could not be evaluated between 
treatment regimens, was not used as an endpoint in this study due to the inability 
to separate the confounding effects of other chemotherapy treatments. Toxicities 
were evaluated during paclitaxel treatment, recorded prospectively, and coded by 
NCI CTC AE V4.0 based on the physician’s description(149). Patients who were 
treated at outside institutions did not have toxicity data and were excluded from 
that part of the analysis. All patients signed informed consent to participate and 
agreed to allow DNA to be collected for additional pharmacogenetic studies. The 
study protocol was approved by the UNC Institutional Review Board.  
SNP Genotyping 
A 30 mL blood sample was collected from each subject at the time of 
study enrollment. DNA used for genotyping was extracted by the UNC 
Biospecimen Processing Facility and plated at 5 ng/uL. Target gene region 
amplification was carried out by PCR in a 20 μL reaction including 2 μL genomic 
DNA and polymorphisms were genotyped on a Pyromark Pyrosequencer Q96 
MD as previously described (223, 224). The polymorphisms genotyped were as 
 106 
 
follows: CYP1B1*3 (rs1056836, 4326C>G), CYP2C8*3 (rs11572080, 416G>A 
and rs10509681, 1196A>G), CYP3A4*1B (rs2740574, -392A>G), CYP3A5*3C 
(rs776746, 6986A>G), and ABCB1*2 (rs1045642, 3435C>T, rs2032582, 
2677G>T/A, and rs1128503, 1236C>T). Genotyping was carried out blinded to 
clinical data with negative controls included in each run and at least 5% of 
samples were repeated for quality control to ensure accuracy of assay results. 
Any assay with call rate or concordance with repeated samples <95% was 
excluded from analysis.  
CYP3A4*1B/CYP3A5*3C and ABCB1 1236C>T, 2677G>T/A, and 
3435C>T were included in haplotype analyses. Haplotypes were inferred using 
PHASE Version 2(225, 226) for polymorphisms with LD>0.7. Any subject with 
missing genotype information at any locus of the haplotype was considered to 
have an unknown haplotype and excluded from analysis. CYP3A4/3A5 
haplotypes were grouped according to Baker et al. (*1: CYP3A4*1A/CYP3A5*3C, 
*2: CYP3A4*1B/CYP3A5*1A, *3: CYP3A4*1A/CYP3A5*1A, *4: 
CYP3A4*1B/CYP3A5*3C)(19). After ABCB1 haplotype inference (Wild-type: C-
G-C, Variant: T-T(A)-T, Mixed: other) each patient was assigned a diplotype 
number (1-5) in order of increasing genetic variation as described in Sissung et 
al.(140). 
Statistical Analysis   
Genotype calls were assessed for concordance with Hardy-Weinberg 
Equilibrium (HWE) using a Pearson chi-square test with D.f.=1. Assays with 
HWE p-value <0.05 in the cohort were then tested in the Caucasian subcohort as 
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population admixture violates key assumptions of Hardy-Weinberg 
Equilibrium(157). Each genotype or haplotype was individually tested for an 
association with efficacy or toxicity using logistic regression modeling. In the 
haplotype analysis, the “variant” group was defined by grouping diplotypes. For 
CYP3A4/3A5 any individual carrying the *2 haplotype (CYP3A4*1B/CYP3A5*1A) 
was considered a variant carrier. For ABCB1 any individual with diplotype 4 or 5 
was considered a variant carrier and was compared to non-carrier diplotypes 1-3. 
For the genotype analyses, variant carriers were compared to homozygotic wild-
type individuals (dominant genetic model). The primary efficacy endpoint was 
clinical complete response (cCR) to taxane therapy (Yes vs. No). The primary 
toxicity endpoint was any grade 3 or higher adverse event during taxane therapy 
(Yes vs. No). Secondary endpoints of efficacy and toxicity were clinical response 
rate (cRR; cCR+cPR=cRR) and grade 3 or higher neuropathy during paclitaxel 
therapy, respectively. Following univariate testing, additional covariates for 
efficacy (estrogen receptor (ER) status, tumor grade, concurrent trastuzumab 
treatment, whether paclitaxel treatment was preceded by other chemotherapy 
phase) were included in a multivariable model to adjust for their prognostic 
importance. Backward selection was used to eliminate covariates that did not 
significantly contribute to the model using AIC as a selection criterion. Self-
reported race was used as stratification factor for significant associations to 
account for racial heterogeneity in the cohort. In order to correct the primary 
efficacy analysis for multiple comparisons the p-values were multiplied by 7, the 
number of independent statistical associations performed, (a Bonferroni 
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correction for multiple comparisons) so that the p-value to be compared to the 
standard significance threshold of α=0.05 is valid. P-values of all secondary and 
sub-analyses are uncorrected as these are exploratory in nature and should be 
interpreted as such. All statistical analyses were performed in R Statistical 
Software, version 2.13.0 (R Development Core Team, Vienna, Austria).  
RESULTS 
Patient Population 
111 patients treated neoadjuvantly with paclitaxel-containing regimens 
were eligible for analysis. After excluding subjects missing efficacy or toxicity 
data, 103 subjects were included in the efficacy and 109 subjects in the toxicity 
analysis. Demographic data including patient, treatment, and tumor 
characteristics for the whole population are presented in Table 10.  
Allele Frequencies 
The two highly linked SNPs in CYP2C8*3 (rs11572080, 416G>A and 
rs10509681, 1196A>G) were completely concordant in this population. CYP3A4 
and CYP3A5 were out of Hardy Weinberg Equilibrium prior to accounting for 
race, as expected given the large difference in allele frequencies among 
Caucasian and African-American individuals(227), but no significant deviations 
were seen in stratified samples. Allele frequencies in Caucasian subjects for all 
variants were consistent with those reported in The International HapMap 
Project(159) or the NCBI EntrezSNP database(228) and replicated samples were 
100% concordant with the original genotype calls, thus no assays were excluded 
from analysis (Table 11). As expected, significant LD was seen between 
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CYP3A4*1B and CYP3A5*3C (r=0.93) and the three polymorphisms in ABCB1 
(r>0.7), which were then grouped into haplotypes as planned (Table 12).  
Response by Genotype 
Clinical complete response to paclitaxel for the efficacy cohort was 30.1% 
and the mean change in tumor size was a 49% reduction (Table 13). Response 
by genotype is presented in Table 14, demonstrating significance only for 
CYP2C8; the odds ratio for an individual carrying CYP2C8*3 to achieve clinical 
complete response was 3.92 with a 95% confidence interval of 1.46-10.48 
(corrected p=0.046) (Figure 20). Of the 22 subjects carrying the CYP2C8*3 
variant, 12 achieved clinical complete response (55%) as compared to only 19 
out of the 81 wild-type subjects (23%). In order to ascertain whether this 
association was independent of other prognostic factors a multivariable model 
that included tumor grade, ER status, concomitant trastuzumab, and whether 
paclitaxel was preceded by another phase of chemotherapy was tested. After 
backward elimination of covariates that were not significant, the final model 
included tumor grade and whether paclitaxel was preceded by another phase of 
chemotherapy. After controlling for these prognostic factors the association of 
CYP2C8*3 status remained significant in the final model (uncorrected p=0.003, 
corrected p=0.022) while the other covariates were not significantly associated 
with achievement of clinical complete response (Table 15). Next, the association 
of CYP2C8*3 and clinical complete response was stratified by race to ensure that 
racial heterogeneity was not falsely inflating our results. In the self-reported 
Caucasian subjects the magnitude of effect was marginally greater and the 
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significance similar to that seen in the entire efficacy cohort (OR=5.31, 95% CI: 
1.59-17.67, corrected p=0.049). Only two non-Caucasians carried the *3 variant 
in our cohort so the association in non-Caucasians was not analyzed.  
To evaluate the robustness of our finding, a secondary efficacy analysis 
was carried out with clinical response rate (cRR=cCR+cPR). The clinical 
response rate in the cohort was 63% (65/103). In the CYP2C8*3 carriers the 
response rate was 82% (18/22) vs. 58% (47/81) in the CYP2C8 wild-type 
subjects. In the univariate logistic regression model this association showed a 
strong trend in the same direction with an odds ratio of 3.16 (95% CI: 0.98-10.19, 
uncorrected p=0.054), supporting our primary findings.  
In order to examine whether, as hypothesized, this finding was specific to 
paclitaxel, we then tested the association between CYP2C8*3 status and clinical 
complete response to the doxorubicin-cyclophosphamide (AC) phase of therapy 
in patients who received the combination. Out of 100 subjects who received the 
AC combination who had evaluable response, the rate of clinical complete 
response was not significantly different between *3 carriers (2/22=9.0%) and 
wild-type homozygotes (8/78=10.3%) (OR=1.14, 95% CI: 0.62-15.96, 
uncorrected p=0.872).  
Toxicity by Genotype 
Of the 109 subjects included in the toxicity analysis, 34 experienced at 
least one grade 3 or higher toxicity (31.2%) (Table 16), however, none of the 
genetic markers were associated with this cumulative endpoint (data not shown). 
Analysis of the secondary toxicity endpoint, grade 3 or higher peripheral 
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neuropathy, revealed a trend toward increased neuropathy in subjects carrying 
the CYP2C8*3 variant (5/23=22%) vs. wild-type individuals (7/86=8%) (OR=3.13, 
95% CI: 0.89-11.01, p=0.075) (Figure 21, Table 17).  
DISCUSSION 
This study investigated pharmacogenetic predictors of breast cancer 
treatment outcomes following neoadjuvant paclitaxel. By measuring the tumor 
before and after each phase of sequential chemotherapy, and collecting toxicity 
during each phase separately, we were able to isolate the taxane-specific 
outcomes from the sequential therapy. We employed a candidate polymorphism 
replicate strategy based on reported associations with clinical outcomes in 
previous pharmacogenetic studies in taxane treated cancer patients. These 
candidate genes covered the major metabolic pathways of paclitaxel, 
CYP3A4/3A5 and CYP2C8, the efflux transporter ABCB1, and CYP1B1 which 
has been shown to influence taxane treatment efficacy.  
Our results indicate that patients carrying the CYP2C8*3 polymorphism 
are more likely to achieve clinical complete response than patients homozygous 
for the wild-type isozyme. This finding is supported by the strong trend in the 
same direction for clinical response rate. The association with tumor response 
remained significant after adjustment for covariates and stratification by self-
reported race. There was no association between CYP2C8 genotype and clinical 
complete response to the AC phase of sequential therapy, dismissing the 
possibility that patients carrying CYP2C8*3 had more chemosensitive tumors. 
Thus, there seems to be a true pharmacogenetic association between the 
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CYP2C8*3 polymorphism and clinical response to neoadjuvant paclitaxel 
therapy. 
Clinical response, instead of the more accepted pathological response, 
which has prognostic implications for future survival(229-231), was selected due 
to the collection of tumor size data between phases of sequential therapy, which 
enables us to isolate the response to the paclitaxel phase of treatment from that 
of the other administered therapy. Although clinical measurement is not a 
component of RECIST classification, that methodology was designed with 
radiographic measurements in the metastatic setting in mind. Conversely, 
pathologic response, a more conventional endpoint for neoadjuvant studies, 
cannot differentiate among drugs given preoperatively so would have introduced 
considerable noise from the inclusion of anthracycline and antimetabolite effect in 
the efficacy estimates. Moreover, the ability to use response to the AC 
component of therapy as an internal control for the specificity of the findings for 
paclitaxel would have been lost. There is a documented relationship between 
clinical measurement and pathologic response(232) supporting the use of easily 
obtained serial clinical measurements in the palpable lesions relevant in this 
setting. The reported relationship between clinical and pathological response 
indicates that our finding may have an important influence on survival; however, 
it is essential that these findings are confirmed with pathological or radiographic 
tumor measurements before and after taxane therapy in independent patient 
cohorts.  
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Two previous groups have reported that patients carrying CYP2C8*3 are 
at a higher risk of paclitaxel-induced peripheral neuropathy(131, 132), but this 
finding was not observed in other studies(134, 135, 137). All of these studies 
primarily included patients who were on combination therapy or who had been 
previously treated with chemotherapy. Our results, in previously untreated 
patients not receiving combination therapy with other neurotoxins, are consistent 
with those of Leskela et al. and Gréen et al. and suggest that there may be a true 
association between CYP2C8*3 and risk of peripheral neuropathy. The 
difference between our study and that of Leskela et al. is the event rate. Their 
study included grade 2+ neurotoxicity, a substantially more common phenotype 
than our grade 3+ endpoint, but one that does not require a change in therapy, 
unlike higher grades of neuropathy as were measured in this study. Additionally, 
they used a cumulative dose-to-event analysis, which is consistent with the 
cumulative nature of neurotoxicity. This was not feasible in our study given the 
relatively small number of patients (12) who experienced grade 3 or higher 
neuropathy. In fact, it is important to note that a general limitation of the current 
study is the modest sample size.  
The paclitaxel parent compound, not its metabolites, is thought to be 
responsible for the drug’s efficacy and toxicity(30). Paclitaxel clinical outcomes 
are related to the amount of time the total drug concentration remains above a 
threshold level(95, 233) and the cumulative exposure may determine the extent 
of neuropathy development(91, 172). The CYP2C8*3 variant has diminished in 
vitro metabolic activity for paclitaxel(153, 205, 234, 235) and carriers of this 
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variant have decreased clearance of free paclitaxel, and a corresponding 
increase in drug exposure(155). These findings provide a rational mechanism for 
the increased paclitaxel treatment response and toxicity seen in CYP2C8*3 
carriers in this study.  
It is not possible to distinguish the influence of each of the two non-
synonymous polymorphisms in CYP2C8*3 in this population due to complete 
concordance, and it will be difficult to do this in any clinical study based on their 
high linkage disequilibrium. However, in vitro data suggests that the causative 
SNP is the K399R variant (rs10509681) which, unlike the R139K variant, has 
diminished paclitaxel metabolic activity when each is tested in isolation(153, 
154). If this were true, then it would be important for future researchers to focus 
their analyses specifically on the K399R variant which is sometimes present in 
patients without the R139K variant(152).  
These patients were treated according to standard neoadjuvant protocols, 
which specify an appropriate treatment dose, schedule, and duration. Recent 
data demonstrates that the 3-weekly regimen received by 20% of these patients 
is inferior to the weekly or every-2 week regimen(97). In follow-up analyses, 
multivariable models that included treatment schedule were analyzed to see if 
schedule had a significant influence on the achievement of clinical complete 
response, which it did not (uncorrected p=0.100, data not shown). The pre-
defined treatment duration also ensures that the assessment of response and 
neuropathy are not confounded by dramatic differences in cumulative paclitaxel 
received. Only 12 patients discontinued paclitaxel before receiving the full course 
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of therapy, 11 for toxicity and 1 due to disease progression during treatment. 
Indeed, carriers of the CYP2C8*3 variant received a similar number of cycles 
(median=4) and weeks of therapy (mean= 9.99 vs. 9.60) compared with wild-type 
patients so it is unlikely that differences in response or neurotoxicity are 
attributable to differences in cumulative paclitaxel administered.  
Numerous groups have investigated polymorphisms in other genes 
relevant to paclitaxel exposure or mechanism. The polymorphisms in CYP3A4 
and CYP3A5 have been interrogated independently and typically do not show 
associations with outcome(134, 219, 236), though associations have been 
reported(175). However, recent data suggests that looking at the 
CYP3A4*1B/3A5*1A variants as a high metabolic activity haplotype may be a 
superior strategy(19). We were unable to identify a statistically significant 
association with paclitaxel treatment outcomes for either the CYP3A4*1B variant 
alone or the two variants in combination.  
The ABCB1 variants have also been the focus of a number of 
retrospective pharmacogenetic studies, with inconsistent results. Variants at the 
3435 position have been associated with shorter overall survival and worse 
progression free survival in paclitaxel treated cancer patients(173, 174). Variants 
at the 3435 and 2677 position have been implicated in higher risk of paclitaxel-
induced neutropenia(139) and docetaxel treatment outcomes(140). In our study 
the variants of ABCB1 tested individually or in haplotypes did not have a 
statistically significant effect on paclitaxel treatment outcome. 
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CYP1B1 is not involved in taxane metabolism(237), yet an association 
between taxane efficacy and the CYP1B1*3 variant has been demonstrated 
repeatedly(219, 238-240). In vitro studies by Sissung et al. reveal that CYP1B1*3 
enhances estrogen metabolism to compounds that antagonize the mechanism of 
action of docetaxel and paclitaxel, and covalently bind docetaxel, providing two 
plausible mechanisms for the decreased efficacy seen in patients with this 
genotype. We found no evidence of a link between CYP1B1 genotype and 
paclitaxel efficacy. 
In conclusion, we report evidence that CYP2C8*3 carriers are more likely 
to achieve complete clinical response to neoadjuvant paclitaxel. This association 
was independent of other important clinical covariates. The odds of an individual 
who carried the *3 variant achieving clinical complete response were nearly 4 
times higher than those for an individual carrying two wild-type alleles. 
Additionally, our results support the previously reported possibility that individuals 
carrying this variant are at increased risk of experiencing paclitaxel related 
neuropathy. Our data suggests a potential biomarker for identifying patients 
before treatment who are more likely to benefit from therapy, but may be at an 
increased risk of experiencing certain adverse events. The results of this small 
study warrant further investigation of this association in larger neoadjuvantly 
treated patient cohorts, and if confirmed may prompt studies of dose 
individualization based on host genotype. 
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TABLES 
Table 10 Patient Characteristics of LCCC9830 Neoadjuvant Cohort 
Self-reported 
Race  
Caucasian 79 (71%)  
African-American 27 (24%)  
Other  5 (5%)  
Age (Years)  
Median 50 (11.2) 
Range  27-78  
Menopausal 
Status  
Pre-menopausal 57 (51%)  
Post-menopausal 54 (49%)  
Grade at 
Diagnosis  
1  7 (6%)  
2  29 (26%)  
3  60 (54%)  
Unknown  15 (14%)  
Receptor 
Status  
ER+ 56 (50%)  
ER or PR+  63 (57%)  
HER2+  31 (28%)  
Stage at 
Diagnosis  
IIA-IIB 42 (38%)  
IIIA-IIIC  59 (53%)  
IV  10 (9%)  
Taxane 
Regimena 
T 16(14%) 
TC 2 (2%) 
TCH 1 (1%) 
TH 1 (1%) 
AC-T 73 (66%) 
AC-TH 18(16%) 
Taxane 
Schedule and 
Dose  
Weekly (80-
90mg/m2) 
36 (32%)  
Q2 Weeks 
(175mg/m2) 
52 (47%)  
Q3 Weeks 
(175mg/m2) 
22 (20%)  
Q2.5 Weeks 
(175mg/m2) 
1 (1%)  
Early Paclitaxel 
Discontinuation 
Toxicity  11 (10%) 
Disease Progression  1 (1%) 
Total Weeks of 
Taxane  
Median 9.0 (2.9)  
Range  1-23  
Abbreviations: A, Doxorubicin (Adriamycin); C, Cyclophosphamide (Cytoxan); T, 
Paclitaxel (Taxol); H, Trastuzumab (Herceptin) 
a: Regimen includes all drugs taken before or during paclitaxel treatment 
‘-‘ indicates these are sequential treatments 
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Table 11 LCCC 9830 Neoadjuvant PGx Study Genotyping Results 
Gene 
Variant 
Amino Acid 
or Base 
Change 
Call 
Rate 
Variant 
Allele 
Frequency 
Hardy-
Weinberg 
Equilibrium 
P-value 
Variant AF 
in 
Caucasians 
Expected 
AF in 
Caucasiansa 
CYP1B1*3  99.1% 0.53 0.136 0.45 0.45 
CYP2C8*3 
R139K 100% 0.11 0.574 0.14 0.13 
K399R 100% 0.11 0.574 0.14 0.14 
CYP3A4*1B  100% 0.17 <0.001 0.04 0.03b 
CYP3A5*3C  99.1% 0.80 <0.001 0.94 0.96 
ABCB1*2 
1236C>T 100% 0.38 0.913 0.43 0.45 
2677G>T/A 99.1% 0.34 0.140 0.44 0.47 
3435C>T 98.2% 0.42 0.533 0.51 0.57 
aReported from International HapMap Project for Caucasian (CEU) population  
bEstimated from Caucasian/CEPH populations in dbSNP  
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Table 12: Haplotype Grouping for CYP3A4/3A5 and ABCB1 
Gene Diplotype Number 
CYP3A4/3A5 
*1/*1 76 
*1/*3 5 
*1/*4 3 
*3/*3 1 
*1/*2 11 
*2/*2 8 
*2/*3 5 
*2/*4 1 
Unknown 1 
*2 Carrier 25 
*2 Non-Carrier 85 
ABCB1 
1 30 
2 21 
3 31 
4 13 
5 11 
6 1 
7 1 
8 0 
9 0 
10 0 
Unknown 3 
1-3 82 
4-5 24 
Excluded 5 
Complete breakdown of number of individuals who fall into 
each haplotype category as defined for CYP3A4/3A5 in Baker 
et al. (19) and ABCB1 in Sissung et al. (140)  followed by the 
grouping for the association study. (CYP3A4/3A5 *2 carriers 
vs. other and ABCB1 Diplotype 1-3 vs. 4&5). 
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Table 13 Response to Paclitaxel Therapy in LCCC 9830 Neoadjuvant PGx 
Efficacy Cohort 
% Change 
in Tumor 
Size 
Mean -49% 
Median -43% 
Maximum Decrease 100% 
Maximum Increase 29% 
Clinical 
Response 
Clinical Complete Response 31 (30.1%) 
Clinical Partial Response 34 (33.0%) 
Clinical Stable Disease 36 (35.0%) 
Clinical Progressive Disease 2 (1.9%) 
Excluded (Unevaluable) 8 
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Table 14 Association of Genotype and Haplotype with Clinical Complete 
Response in LCCC 9830 Efficacy Cohort 
Gene Variant Odds Ratio 
 (95% CI) 
Uncorrected  
p-value 
Bonferroni 
Corrected p-
value 
CYP1B1*3 0.53 (0.21-1.33) 0.1761 1.0000 
CYP2C8*3 3.92 (1.46-10.48) 0.0066 0.0459 
CYP3A4*1B 0.88 (0.32-2.37) 0.7929 1.0000 
CYP3A4/3A5 Haplotype 1.16 (0.42-3.21) 0.7798 1.0000 
ABCB1 3435 1.23 (0.50-3.01) 0.6548 1.0000 
ABCB1 2677 1.98 (0.83-4.73) 0.1245 0.8716 
ABCB1 Haplotype 0.49 (0.15-1.61) 0.2389 1.0000 
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Table 15 Final Multivariable Model of Clinical Complete Response in LCCC 9830 
Neoadjuvant PGx Efficacy Cohort 
 Odds 
Ratio 
95% Confidence 
Interval 
Uncorrected  
P-value 
CYP2C8 5.11 1.73-15.12 0.003 
Tumor grade 1.08 0.50-2.35 0.840 
Preceded by another phase of 
chemotherapy 
0.59 0.19-1.79 0.350 
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Table 16 Grade 3+ Toxicities During Paclitaxel Treatment in LCCC 9830 Toxicity 
Cohort 
Any 
Toxicity 
Any 34 (31%) 
None 75 (69%) 
Excluded 2 
Specific 
Toxicities 
Neuropathy 12 (11%) 
Neutropenia 10 (9%) 
Myalgia 9 (8%) 
Hypersensitivity 7 (6%) 
Fatigue 4 (4%) 
Gastrointestinal 3 (3%) 
Anemia 2 (2%) 
Other 4 (4%) 
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Table 17 Association of Genotype and Haplotype with Grade 3+ Neuropathy in 
LCCC 9830 Neoadjuvant PGx Toxicity Cohort 
Gene 
Odds Ratio (95% 
Confidence Interval) 
Variant Carrier 
vs. Wild-type 
uncorrected p-value 
CYP1B1*3 0.76 (0.18-2.41) 0.537 
CYP2C8*3 3.13 (0.89-11.01) 0.075 
CYP3A4*1B 1.01 (0.25-4.05) 0.984 
CYP3A4/3A5 Haplotype 1.19 (0.30-4.80) 0.806 
ABCB1 3435 6.71 (0.83-54.19) 0.074 
ABCB1 2677 2.41 (0.60-9.61) 0.214 
ABCB1 Haplotype 0.76 (0.15-3.80) 0.740 
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FIGURE LEGENDS 
 
Figure 20 Percentage of patients carrying CYP2C8*3 vs. CYP2C8*1 wild-type 
homozygotes achieving clinical complete response. Patients carrying CYP2C8*3 
were more likely to achieve clinical complete response (OR=3.92, 95% CI: 1.46-
10.48, corrected p=0.046).   
 
Figure 21 Percentage of patients carrying CYP2C8*3 vs. CYP2C8*1 wild-type 
homozygotes experiencing severe peripheral neuropathy. There was a trend 
toward greater risk of severe neuropathy in patients carrying the *3 variant, 
though it did not achieve statistical significance (OR=3.13, 95% CI: 0.89-11.01, 
uncorrected p=0.075)   
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FIGURES 
Figure 20 Clinical Complete Response by CYP2C8 Genotype in LCCC 9830 
Neoadjuvant PGx Study Cohort
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Figure 21 Grade 3+ Neuropathy by CYP2C8 Genotype in LCCC 9830 
Neoadjuvant PGx Cohort  
Daniel L. Hertz, Christine M Walko, Arlene S Bridges, J. Heyward Hull, Jill 
Herendeen, Kristan Rollins, Paul B Watkins, E. Claire Dees. Published in Br J 
Clin Pharmacol. 2012 Jul;74(1):197-200 
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APPENDIX 2 
PILOT STUDY OF ROSIGLITAZONE AS AN IN VIVO PROBE OF 
PACLITAXEL EXPOSURE  
INTRODUCTION 
Interpatient variability in toxic and therapeutic response to chemotherapy, 
partially caused by differences in the activity of the CYP450 enzyme system, is a 
substantial problem in cancer treatment. One emerging approach to characterize 
a drug’s metabolism is through the use of a probe; a marker agent that shares 
the drug’s metabolic pathway. Probe-based tests to measure CYP450 phenotype 
that are safe, easy to administer, and quickly interpretable have been developed 
for some enzymes(241) relevant to anti-cancer therapy but not all.   
Paclitaxel is one of the most effective chemotherapeutic agents used in 
the treatment of solid tumor malignancies. It is metabolized to inactive 
metabolites primarily by CYP2C8 with a contribution from CYP3A4(30). A probe 
assay that could explain the significant interpatient variability in paclitaxel 
exposure might help clinicians choose a more appropriate dosage for an 
individual patient to optimize efficacy and limit toxicity.  
The erythromycin breath test (ERMBT) has been widely implemented to 
measure hepatic CYP3A4 activity(242), however, there is no such probe for 
CYP2C8. Interestingly, the rates of rosiglitazone metabolism and paclitaxel 
hydroxylation have been shown to correlate in human liver microsomes 
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expressing CYP2C8(243). In healthy subjects, a 2 mg oral dose of rosiglitazone 
is safe, >99% bioavailable, and the plasma concentration at 3 hours is highly 
predictive of AUC0-inf (r
2=0.98) (Clarke, S.:  GlaxoSmithKline, Personal 
communication), making rosiglitazone an attractive probe candidate.   
Despite the known in vitro correlation, rosiglitazone has not been 
previously used as a probe for CYP2C8 to predict paclitaxel exposure in patients. 
In this study we used rosiglitazone and ERMBT as surrogates of CYP2C8 and 
CYP3A4 activity, respectively, and hypothesized that the combination of these 
probes would explain the variability in paclitaxel exposure in cancer patients.   
METHODS 
This study was conducted at the General Clinical Research Center 
(GCRC) and approved by the Institutional Review Board at UNC Chapel Hill. 
Eligible patients were > 18 years old with solid tumor malignancies, were 
scheduled to receive weekly paclitaxel, and provided written informed consent.  
On study day 1, Erythromycin Breath Test (ERMBT) was carried out as 
previously described(244). The percentage of the dose exhaled as 14C over 1 
hour (AUC0-1) was loge (Ln) transformed and used as a measure of CYP3A4 
activity. Each subject (all of whom fasted for > 6 hours) was then administered a 
2 mg oral dose of rosiglitazone. A blood sample was collected 3 hours after 
dosing and plasma concentration analysis was performed as previously 
described(245). Rosiglitazone concentrations at 3 hours (rosi3) were adjusted to 
a standard dose per median body surface area (BSA) [1.80 mg/m2], Ln 
transformed, and used as a measure of CYP2C8 activity.   
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Approximately 6 hours after the rosiglitazone dose, each subject was 
administered a one-hour infusion of paclitaxel (75 mg/m2 to 90 mg/m2) as per 
their standard treatment. Blood samples (7 mL) were collected prior to infusion 
and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, and 6 hours after the start of infusion. Limited 
sampling, which enables reasonably accurate estimation of paclitaxel 
exposure(246), was employed for patient convenience. An additional sample was 
collected 18-24 hours post infusion for estimation of AUC0-inf. Plasma was 
separated and stored at -80°C before undergoing analysis via LC/MS/MS as 
previously described to measure total paclitaxel concentration(247). 
Paclitaxel pharmacokinetic analysis was performed in WinNonlin Pro 
Version 5.2.1 (Pharsight Corp., Mountain View, CA) using non-compartmental 
methods. Concentration values were adjusted to a standard dose per median 
BSA [79.7 mg/m2]. AUC0-6 was calculated using the linear trapezoidal method 
and Ln transformed for use in the primary analysis. All later discussion refers to 
normalized concentrations.     
Statistical analysis was conducted in SAS 9.2 (SAS Institute Inc, Cary, 
NC) using a multiple regression model with rosi3 and ERMBT AUC0-1 the 
independent variables and paclitaxel AUC0-6 the dependent variable.   
RESULTS 
Twenty (20) patients with planned or ongoing weekly paclitaxel treatment 
were enrolled. Demographic data for the 14 subjects who had evaluable samples 
for paclitaxel pharmacokinetic analysis are displayed in Table 18. The mean 
(±SD) paclitaxel AUC0-6 was 6,646 (±2,454) ng*hr/ml, ERMBT AUC0-1 was 2.76 
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%/hr (±1.2) and rosi3 was 81.8 (± 25.9) ng/mL. In the two-variable regression 
model rosi3 was a statistically significant predictor of paclitaxel AUC0-6 (p=0.019); 
however, ERMBT was not (p=0.47). After exclusion of ERMBT, rosi3 alone 
explained about 38% of the variability in paclitaxel AUC0-6 (r
2=0.38, p=0.018, 
Figure 22). In follow-up exploratory analyses no other relevant covariates (e.g., 
age, albumin, cancer type, and smoking status) significantly contributed to the 
model (data not shown).   
DISCUSSION 
In this pilot study, a 3-hour rosiglitazone plasma concentration after a 2 
mg oral dose explained 38% of the variability in paclitaxel exposure. As 
expected, higher rosiglitazone concentration was associated with increased 
paclitaxel exposure. This is the first report of an in vivo association between 
rosiglitazone and paclitaxel exposure and supports the hypothesis that 
rosiglitazone may be a reasonable probe for in vivo exposure to CYP2C8 
substrates.   
Because this was a small pilot study, additional secondary analyses of the 
data were conducted to investigate the robustness of our findings; with results 
consistent with the primary finding. Using paclitaxel AUC0-6 and rosi3 without 
dose normalization had little impact on our primary finding (r2=0.33, p=0.029). 
The correlation between paclitaxel AUC0-inf and AUC0-6 was strong (r
2=0.92) and 
use of Ln AUC0-inf instead of Ln AUC0-6 did not meaningfully change the results 
(r2=0.32, p=0.034). A slightly stronger relationship was found (r2=0.51, p=0.004) 
when paclitaxel AUC0-6 and rosi3 were transformed to ranks prior to regression, 
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suggesting that the findings did not result from the impact of a particularly 
influential value.   
The highest rosiglitazone concentration seen was 120 ng/mL while 
rosiglitazone’s reported Ki is 1,998 ng/mL(248), thus same-day administration of 
rosiglitazone and paclitaxel are unlikely to have resulted in competitive enzyme 
inhibition. In a similar study ERMBT explained 67% of the variability in docetaxel 
clearance(242), which is metabolized exclusively by CYP3A4. Our finding that 
ERMBT was not predictive of paclitaxel clearance is consistent with other 
evidence that CYP2C8 is the primary enzyme responsible for paclitaxel 
metabolism in most patients. It is possible that in a larger study a CYP3A4 probe 
may explain some of the residual variability in paclitaxel exposure unexplained by 
rosiglitazone. It is also likely that a portion of our unexplained variability can be 
attributed to the role of drug transporters in the pharmacokinetics of ERMBT and 
paclitaxel(249).  
In conclusion, this report supports further study of rosiglitazone as an in 
vivo probe of CYP2C8 activity in humans. In particular, rosiglitazone may have a 
role in guiding dosing of CYP2C8 substrates that have a narrow therapeutic 
index, such as paclitaxel, particularly in elderly patients and others who 
historically have been empirically dose-reduced.   
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TABLES 
Table 18 Demographic and Clinical Characteristics of Rosiglitazone Probe 
Study Patients 
 Study Population (n=14) 
Gender 
Female 11 (79%) 
Male 3 (21%) 
Ethnicity 
Caucasian  12 (86%) 
African-American  1 (7%) 
Other 1 (7%) 
Age Median (Range) 47 (25-64) 
BSA (m2) Median (Range) 1.80 (1.51-2.33) 
Cancer Type 
Breast 4 (29%) 
Lung 6 (43%) 
Melanoma 2 (14%) 
Ovarian 1 (7%) 
Other 1 (7%) 
Paclitaxel Dose 
(mg/m2/week) 
Median (Range) 79.7 (75-90) 
Concomitant Therapy* 
Herceptin 4 (29%) 
Carboplatin 6 (43%) 
None 4 (29%) 
*Neither agent is known to modulate CYP2C8 or CYP3A4 activity. 
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FIGURE LEGENDS 
Figure 22 Relationship between Ln rosiglitazone 3-hour concentration and Ln 
paclitaxel AUC0-6 (n=14). Concentrations of both drugs were adjusted to a 
standard (median) dose per BSA.  
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FIGURES 
Figure 22 In Vivo Correlation Between Paclitaxel and Rosiglitazone Exposure  
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